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A. List of abbreviations 
Less frequently used abbreviation are defined upon their first use in the text. 
BBB                                        Blood-brain-barrier  
bFGF                                       Basic fibroblast growth factor 
ECM                                       Extracellular matrix 
EGFR                                      Epidermal growth factor receptor  
Gas6                                        Growth arrest-specific gene 6 
GBM                                       Glioblastoma multiforme 
MAPK                                    Mitogen-activated protein kinase 
MerTK                                    Mer tyrosine kinase 
MLC2                                     Myosin light chain 2 
MMPs                                     Matrix metalloproteinases 
mTOR                                     Mammalian target of rapamycin 
PDGFR                                   Platelet-derived growth factor receptor 
PI3K                                       Phosphoinositide-3-kinase 
PKB                                        Protein kinase B 
PTEN                                      Phosphatase and tensin homolog 
ROCK                                     Rho-associated serine-threonine protein kinase   
RTK                                        Receptor tyrosine kinase 
TAM                                       Tyro3, Axl and Mer 
VEGF                                      Vascular endothelial growth factor 
2D                                           2-dimensional 
3D                                           3-dimensional 
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B.      Summary 
GBM is one of the most aggressive human cancers. Primary GBM, which comprises more 
than 90% of biopsied or resected brain tumors, arises de novo without an antecedent history of 
low-grade disease. In contrast, secondary GBM progresses from previously diagnosed low-grade 
astrocytomas. Despite the implementation of intensive therapeutic strategies and supportive care, 
the median survival of GBM patients over the past decade has remained at ~ 12-14 months. A 
classification scheme based on a comprehensive understanding of the genetic alterations and 
gene expression changes underlying glioma formation has categorized glioblastoma into four 
distinct molecular subtypes: classical, mesenchymal, neural, and proneural. In addition, the role 
of cancer stem-like cells is being actively investigated. A transformed neural stem or glial 
progenitor cell can give rise to tumors, but mature astrocytes can also undergo de-differentiation. 
The diffusive infiltration nature of malignant glioma cells poses a serious clinical challenge 
because such cells are widely believed to be responsible for tumor recurrence after surgery, 
radiation, and chemotherapy.  
MerTK is a member of the TAM receptor tyrosine kinase family, which is characterized by a 
conserved sequence within the kinase domain and a combination of two N-terminal 
immunoglobulin (Ig)-like domains and two fibronectin type III (FNIII) repeats in their 
extracellular regions. Although protein S and Gas6 are the putative ligands of TAM kinases, 
several other proteins have been proposed recently to activate TAM receptors, suggesting the 
existence of additional mechanisms for TAM activation. Full activation of MerTK requires the 
autophosphorylation of tyrosines 749, 753 and 754 within the kinase domain and co-
immunoprecipitation experiments indicate that several signaling molecules associate with 
phosphorylated tyrosine 872 of MerTK in the catalytic domain. MerTK appears to be required 
iii 
 
for ingestion of apoptotic cells by phagocytes such as monocytes/macrophages, and also by 
retinal pigment epithelial cells and dendritic cells. Overexpression of MerTK has been reported 
in many cancer types, including breast and prostate cancer, lymphoma and leukemia. Recently, 
MerTK was found to be upregulated in the mesenchymal subtype of primary GBMs and 
depletion of MerTK increases astrocytoma cell chemosensitivity. Nevertheless, the mechanisms 
of MerTK activation and its activity in brain tumor progression remain unclear. 
In this study, MerTK was found to be overexpressed in GBM and GBM-derived spheres 
compared with non-neoplastic brain tissue and normal human astrocytes, and this is mitigated 
upon differentiation. Low expression of MerTK was also observed in conventional immortalized 
GBM cell lines. Co-staining MerTK with the astrocytic marker GFAP (glial fibrillary acidic 
protein) indicates that MerTK is expressed in the GFAP+ cell lineage in GBM samples. MerTK 
maintains the amoeboid rounded morphology of GBM cells under stem cell culture conditions 
and MerTK is upregulated in U373 GBM cells cultured in serum-free NBM (neural basal 
medium). In vivo studies have shown that glioma cells migrate in an amoeboid mode due to 
structural constraints in the neural ECM. Immunofluorescence staining of U373 cells shows 
intensive blebbing of the cell membrane, which is a typical morphological marker of amoeboidly 
migrating cells. Knockdown of MerTK not only disrupts rounded cell morphology but also 
decreases cell infiltrative capacity and increases cell sensitivity to etoposide-induced apoptosis. It 
was further shown that MerTK autophosphorylation is essential for its anti-apoptotic and pro-
invasive activities. Depletion of MerTK attenuates the expression and phosphorylation of MLC2. 
The results obtained have uncovered a novel activity of MerTK in GBM progression and these 
findings promote MerTK as a potential therapeutic target in the treatment of GBM, in 
combination with radio/chemotherapy.  
Introduction  
1 
 
Figure 1. The neuroglial lineage tree. Self-renewing, 
common progenitors are thought to produce committed 
neuronal and glial progenitors that eventually differentiate 
into mature neurons, astrocytes and oligodendrocytes. 
Although the precise cells of origin for diffuse glioma 
variants and medulloblastoma remain largely unknown, a 
selection of likely candidates for each (dashed arrows) is 
indicated. (Taken from (1)). 
Figure 2. Axial T1-weighted post-contrast magnetic resonance 
image (MRI) sequences of a patient with glioblastoma. (A) At 
diagnosis an enhancing multifocal temporal and right 
parietoccipital tumor is seen. (B) The patient received combined 
chemo- and radiation-therapy and achieved a response. (C) The 
tumor recurred 2 years after diagnosis in a diffusely infiltrating 
fashion and the patient died. (Taken from (9)). 
 
1. Introduction 
1.1  Gliomas 
Gliomas, the most common type of brain tumor, have their origin either in the brain or in the 
spine. They arise from mature glial cells, which normally support and protect neural cells, or 
from their less-differentiated precursors (Fig. 1) (1). Thanks to improvements in standard care, 
survival of patients with glioblastoma, which is the most aggressive glioma, has improved in the 
last decade from an average of 10 months to 14 months after diagnosis (2). 
According to the World Health Organization 
(WHO) classification, 4 grades (I, II, III and IV) 
of glioma are distinguished. In contrast to lower 
grades (I and II), high-grade (III and IV) tumors 
are more aggressive and have a worse prognosis. 
Histologically, high-grade gliomas display 
features such as nuclear atypia, increased 
proliferation, microvascular proliferation and 
necrosis (1). Radiologically, malignant gliomas 
appear as masses with irregular contours (Fig. 2). 
Roughly 90% of GBM (Grade IV) arise de novo, 
while 10% originate from lower grade astrocytoma and are known as “secondary” GBM (3).  
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Figure 3. Frequent genetic alterations in three critical signaling pathways. a-c, 
Primary sequence alterations and significant copy number changes for components 
of the RTK/RAS/PI3K (a), p53 (b) and RB (c) signaling pathways are shown. Red 
indicates activating genetic alterations, with frequently altered genes showing deeper 
shades of red. Conversely, blue indicates inactivating alterations, with darker shades 
corresponding to a higher percentage of alterations. For each altered component of a 
particular pathway, the nature of the alteration and the percentage of tumors affected 
are indicated. Boxes contain the final percentages of glioblastomas with alterations 
in at least one known component gene of the designated pathway (Taken from (4)). 
1.1.1 Genetics of malignant gliomas  
Like many other cancer 
cells, gliomas harbor 
multiple chromosomal 
aberrations, nucleotide 
mutations and epigenetic 
modifications that drive the 
development and 
progression of malignant 
transformation. Although 
the traditional pathological 
diagnosis provides a 
valuable approach to 
distinct tumor grades within 
categories of the same 
tumor type, the highly 
heterogeneous nature of GBM tumors results in an inconsistency of clinical outcome within the 
same group of patients. This indicates the existence of further subtypes within each grade. In 
order to identify and classify the major gene alterations in GBM, The Cancer Genome Atlas 
(TGCA) performed multi-dimensional study of over 206 primary GBM tumor tissues (4). 
Comprehensive characterization defined three main signaling pathways that are dysregulated in 
the majority of GBM tumors, including the RTK/RAS/PI3K, p53 and retinoblastoma (RB) 
signaling pathways (4) (Fig. 3). A further important recent development by TCGA was the 
Introduction  
3 
 
Figure 4. Sequential genetic changes observed in the pathogenesis of different subtypes of glioblastoma. Some cells in the 
normal brain undergo genetic alterations, which leads to a population of tumor-initiating cells (TICs), which can then further 
accumulate genetic and epigenetic changes and become brain cancer-propagating cells (BCPC). The latter cells are 
responsible for the formation of glioblastoma. TNF, tumor necrosis factor; HIF, hypoxia-inducible factor; IDH, isocitrate 
dehydrogenase (Taken from (2)). 
genome-wide analysis of 500 untreated primary GBM tumor samples. Based on the expression 
file and genetic data, GBM is now classified into 4 subtypes according to their genetic alterations: 
classical, mesenchymal, neural, and proneural (5) (Fig. 4). All examples of the “classical” 
subtype have a chromosome 7 amplification paired with chromosome 10 loss. EGFR 
amplification is found in 97% of the classical subtype and the homozygous deletion of CDKN2A 
encoding for both p16INK4A and p14ARF is also frequently associated with this subclass. 
Efficacy of the standard treatment for GBM patients after surgery such as radio/chemotherapy 
also shows a high correlation with classical GBM. Secondly, the mesenchymal subclass shows 
high expression of mesenchymal markers coupled with frequent inactivation of NF1, TP53 and 
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PTEN. These tumors are responsive to intensive chemo/radiation therapies. The proneural 
subtype is named after the distinct expression of genes in oligodendrocytic and proneural 
development. Aberrant expression of PDGFRA and a high frequency of IDH1 mutation are the 
two major features of this GBM subtype. Unfortunately, these tumors show the least response to 
standard treatment. Finally, the neural subtype of GBM tumors has high expression of neural 
markers and shows a low degree of infiltration. Notably, all subtypes commonly demonstrate 
dysregulation of the p53, RB and RTK signaling pathways, and tumors do not change subclass 
after recurrence (5).  
 
1.1.2 Radioresistance and invasion of glioma cells 
Although radiotherapy improves the survival of GBM patients compared with the best 
supportive care (6), radioresistance is an age-old problem with many cancers, including 
malignant gliomas. A major challenge with malignant gliomas is that tumor cells escaping 
surgical removal are able to invade adjacent brain tissue, even with intensive radio/chemotherapy. 
In fact, DNA damage was shown to enhance the potential for radioresistance and invasiveness of 
residual tumor cells after surgery (7-9), but the mechanisms underlying tumor radioresistance 
remain unclear.  
Rapidly expanding research on glioma-initiating cells with stem cell characteristics, such as 
long-term self-renewal and the capacity to differentiate, has provided new insight into the 
molecular mechanisms of infiltration, radioresistant glioma growth and recurrence. Although it 
has been shown that CD133
-
 cells can give rise to CD133
+ in vivo (10, 11), CD133 is still the 
most frequently used marker for identification of glioma stem cells. The DNA damage 
checkpoint is preferentially activated in CD133
+ 
tumor cells isolated from glioma xenografts and 
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primary GBM tumor tissues, and radiation-induced DNA damage is more efficiently repaired 
than in CD133
- 
tumor cells (7). Furthermore, inhibition of the checkpoint kinases Chk1 and Chk2 
sensitizes glioma stem cells to ionizing radiation-induced death, indicating that suppression of 
the DNA-damage checkpoint may improve the efficacy of radiotherapy in GBM (7). Other 
markers such as SSEA-1(12), Nestin, Sox2 and Musashi-1 are also used. Nevertheless, further 
investigation of the molecular biology of glioma stem cells is required.  
The invasive nature of glioma cells poses a severe challenge for GBM treatment. The 
diffusing process of glioma cells has characteristics of non-neural carcinoma cells infiltrating 
into the stroma, namely cell detachment from the tumor mass, adhesion to surrounding ECM, 
and degradation or deformation of ECM that allows cell movement (13). Brain parenchyma lacks 
many elements of other organs, such as collagen, fibronectin and type I laminin, and is 
comprised largely of the polysaccharide hyaluronan and a proteoglycan-based matrix (13). The 
uniqueness of the neural ECM may explain the lack of dispersion of tumor cells migrating into 
the brain and also suggests that glioma cells infiltrate into surrounding tissues by distinct 
mechanisms (14).  
Glioma cells migrate along white matter tracts, leading in many cases to invasion of the 
opposite brain hemisphere. Alternatively, they move along the basal lamina of brain blood 
vessels or between the glia limitans and the pia mater. The expression of lysosomal 
hyaluronidases and secretion of proteases by glioma cells leads to the degradation of pre-existing 
ECM. Coupled with the overproduction of neural ECM components, the secretion of novel ECM 
molecules and the expression of new cell-surface receptors for ECM signals, this leads to a 
remodeling of the surrounding matrix and the bypassing of molecular and structural inhibitory 
factors in the neural parenchyma. The result is the dissemination of glioma cells in the brain (14). 
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However, a clinical trial using MMP inhibitor cocktails was not effective because the inhibition 
of proteolysis caused an amoeboid phenotype in tumor cells, which could then infiltrate through 
the limited extracellular space (15). In the absence of spatial constrains in 2D, glioma cells 
migrate as fibroblasts by the formation of extended lamellipodium without nuclear distortion 
(15). In contrast, given the submicrometer size of the extracellular matrix in neuropil, glioma 
cells invade, like neural progenitor cells, dependent on myosin II activity (15). Although 
inhibition of myosin II strikingly devastates glioma cell migration (15), there is no doubt that the 
motility mechanism of tumor cells within the brain is flexible and reacts to the extracellular 
environment.  
In addition to the effects of ECM on tumor invasion, there is cross-talk between glioma cells 
and neurons, glial, endothelial and immune cells in the tumor microenvironment (16, 17). 
Soluble factors secreted by these cells, including EGF, TGF-α, TGF-β, bFGF, may promote 
glioma cell proliferation, survival and motility (16, 18). It has been widely shown that hypoxia 
conditions accelerate tumor cell migration. Lack of oxygen can activate and stabilize hypoxia-
inducible factor HIF-1α, a well-known transcriptional regulator of glioma angiogenesis and 
invasion (19, 20). Knockdown of HIF-1α was reported to reduce hypoxia-induced glioma cell 
migration and invasion (21).  
 
1.1.3 The current status of glioma treatment 
The dysregulated signaling pathways (Fig. 3) identified in glioma have provided insights into 
many neoplastic molecular alterations and, thus, novel therapeutic targets. This has led to the 
first generation of molecular drugs that inhibit these pathways in the clinical setting. These     
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Table 1. Some targets and molecular agents currently in clinical development for high-grade glioma 
Primary target Agent Other targets Mechanism of action 
EGFR Gefitinib (ZD1839) 
Erlotinib (OSI–774) 
Lapatinib (GW-572016) 
PF-00299804 
BIBW2992 
Cetuximab 
Nimotuzumab 
 
 
HER-2 
HER-2, HER-4 
HER-2, HER-4 
TKI 
TKI 
TKI 
TKI (irreversible) 
TKI (irreversible) 
Monoclonal antibody 
Monoclonal antibody 
EGFRVIII CDX110  Vaccine 
Farnesyl 
transferase 
Lonafarnib (SCH 66336) 
Tipifarnib (R115777) 
 FTI 
FTI 
FGFR Brivanib (BMS-582664) 
Vorinostat (SAHA) 
Valproic acid 
LBH589 
VEGFR2 TKI 
HDAC inhibitor 
HDAC inhibitor 
HDAC inhibitor 
HGF/SF AMG102  Monoclonal antibody 
HSP-90 17-AAG  Blocks HSP-90 ATP 
binding 
Integrins αvβ3, 
αvβ5 
Cilengitide (EMD121974)  Synthetic RGD peptide 
c-Met XL184 VEGFR TKI 
mTOR Sirolimus (rapamycin) 
Everolimus (RAD001) 
Temsirolimus (CCI-779) 
Ridaforolimus (AP23573) 
 mTOR inhibitor 
mTOR inhibitor 
mTOR inhibitor 
mTOR inhibitor 
PDGFR-α IMC3G3  Monoclonal antibody 
PDGFR-β Imatinib 
Dasatinib 
Tandutinib (MLN518) 
BCR/Abl, c-Kit 
Src, BCR/Abl, c-Kit, ephrin A2 
Flt3, c-Kit 
TKI 
TKI 
TKI 
PI3K XL765 mTOR STKI 
PKC Enzastaurin (LY31761)  STKI 
VEGF-A Aflibercept (VEGF Trap) 
Bevacizumab 
VEGF-B, PlGF Soluble decoy receptor 
Monoclonal antibody 
VEGFR-2 Cediranib (AZD2171) 
CT-322 
Pazopanib 
 
Sorafenib 
 
Sunitinib 
Vandetanib (ZD6474) 
XL-184 
All VEGFR subtypes, PDGFR-β, c-Kit 
All VEGFR subtypes 
All VEGFR subtypes, PDGFR-α and β, 
c-Kit 
VEGFR-3, B-Raf, PDGFR-β, c-Kit, 
Ras, p38α 
PDGFR-β, Flt3, c-Kit 
EGFR 
c-Met, RET, c-Kit, Flt3, Tie-2 
TKI 
Adnectin 
TKI 
 
TKI 
 
TKI 
TKI 
TKI 
TKI, tyrosine kinase inhibitor; FGFR, fibroblast growth factor receptor; FTI, farnesyltransferase inhibitor; VEGFR2, vascular 
endothelial growth factor receptor 2; HDAC, histone deacetylase; SAHA, suberoylanilide hydroxamic acid; HGF/SF, hepatocyte 
growth factor/scatter factor; HSP-90, heat shock protein 90; 17-AAG indicates 17-allylamino-17-demethoxygeldanamycin; RGD, 
arginineglycine-aspartate; STKI, serine-threonine kinase inhibitor; PKC, protein kinase C; PlGF, placental growth factor.  
 
agents can be classified into several groups that inhibit growth factor receptors, intracellular 
signaling pathways or angiogenesis (13).  
The most attractive therapeutic target is EGFR, which is overexpressed in over 40% of 
primary GBM, especially of the classical subtype (Fig. 4). The EGFR gene with a deletion of 
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exon 2-7 (EGFRvIII) is ligand-independent constitutively activated (22, 23) and promotes cell 
proliferation, invasion and survival in many cancer types (24-26).  
The PDGFR subtypes α and β and PDGF isoforms (AA, AB, BB, CC, DD) are also 
overexpressed and hyperactivated in malignant gliomas, especially in the proneural subtype (Fig. 
4) (27). The autocrine or paracrine loop of PDGF was shown to promote glioma cell proliferation 
and angiogenesis (13, 28). In addition to growth factor receptors, key components of intracellular 
signaling pathways such as Ras, PI3K/PKB, MAPK, mTOR also provide attractive therapeutic 
targets (13). Moreover, given the high vascularization of GBM tumors, anti-angiogenic drugs 
blocking interactions between secreted pro-angiogenic molecules and their receptors can be 
additional tools for GBM treatment (29).  
GBM is notorious for its biological diversity and histological heterogeneity and, thus, single 
agents targeting one “key” component are unable to cure GBM patients (30). Multi-targeting 
single agents would be a more effective strategy for GBM treatment (Table 1, taken from (2)), 
but the majority of the targeted molecular drugs for GBM examined clinically have been 
disappointing, with no evident prolongation of survival (31). More personalized treatment 
supported by expanding knowledge of glioma genetics will hopefully improve therapeutic target 
selection in the future.  
 
1.2 Cancer cell migration and invasion  
The ability of cancer cells to migrate into or invade surrounding tissues is one of the most 
life-threatening aspects of cancer. Migration requires modification of cell body shape and the 
remodeling of the ECM. Cancer cells disseminate from the primary tumor mass either as single 
cells, with amoeboid or mesenchymal motility, or as cell sheets, strands and clusters by 
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Figure 6. Mesenchymal 
morphology of K4 
sarcoma cells. (Adapted 
from (32)). 
Figure 5. Diversity of tumor invasion mechanisms. (Taken from (33)). 
collective migration. These 
processes are usually influenced 
by transmembrane adhesion 
receptors, matrix-degrading 
enzymes, and cell–cell interaction 
molecules (Fig. 5). Unlike 
Epithelial Mesenchymal 
Transition (EMT), which is a very 
rigid process following relatively 
extensive alterations in gene 
expression, the amoeboid and mesenchymal types of invasiveness are interchangeable modes 
that allow tumor cell motility according to the extracellular environment. The motility mode may 
change at different stages of the invasive process, in parallel to alterations in the 
microenvironment. Further study of the mechanisms mediating Mesenchymal Amoeboid 
Transition/Amoeboid Mesenchymal Transition (MAT/AMT) may provide novel key insights 
into tumor cell invasion/metastasis and trigger concepts for more efficient therapeutic drugs.  
 
1.2.1 Mesenchymal motility 
Mesenchymally migrating cells have a fibroblast-
like spindle-shaped morphology with the formation of 
actin-rich filopodia and lamellipodia at the leading edge 
(32). Generally, mesenchymal migration occurs in five steps: 1. protrusion formation at the 
leading edge; 2. cell-matrix interaction and formation of local contacts; 3. remodeling of ECM 
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Figure 7. Amoeboid 
morphology of A3 
sarcoma cells. 
(Adapted from (32)). 
by recruitment of surface proteases and focalized proteolysis; 4. cell contraction by actomyosin 
dependent on myosin II activity; 5. detachment of the trailing edge (33). In 3D view, cells are 
polarized and display an elongated shape and move with a velocity of approximately 0.1-0.5 
μm/min (34) (Fig. 6). Polymerization of actin is mediated by Rho-family small GTPase Rac and 
cdc42 through regulation of WASP/WAVE proteins (35, 36). The association of Arp2/3 with N-
WASP and WAVE results in Arp2/3 activation and subsequently enhances the nucleation of 
actin filaments and branch formation at the leading edge (37). Focal contacts are mediated by 
integrins that link ECM to the actin cytoskeleton. Integrin clusters recruit many adaptor proteins, 
such as paxillin, vinculin, zyxin as well as protein kinases like Src and FAK, which further 
stabilizes focal adhesion (38). Activation of MMPs and uPA is also necessary for mesenchymal 
migration. Autocrine or paracrine of MMPs have been shown to promote cancer cell invasion in 
vitro and in vivo (39-42).  
 
1.2.2 Amoeboid motility 
Amoeboid migration refers to the specific moving 
mechanism of the amoeba, which is characterized by 
actomyosin-mediated cycles of expansion and 
contraction of the cell body. Amoeboidly migrating cells have a rounded cell morphology in 3D 
(Fig. 7). In higher eukaryotes, amoeboid-like movement is maintained in leukocytes and some 
cancer cells (43-46). The differences between amoeboid and mesenchymal migration are 
summarized in Table 2 (Taken from (33)).  
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Table 2. Differences in cellular and molecular migration mechanisms 
 
Unlike mesenchymal migration, with tight local contacts, amoeboid tumor cells adhere 
loosely to substrates due to low integrin activity (47-50). Instead of degrading ECM, amoeboid-
like invasion is dependent on actomyosin contractility promoted by Rho/ROCK signaling 
pathways (46, 51). Activated Rho can phosphorylate ROCK, which inactivates myosin-light-
chain phosphatase (MLCP) or directly phosphorylates MLC2 (52, 53). In addition, myosin-light-
chain kinase (MLCK) has an antagonistic effect on MLCP, which can also activate MLC2 (53). 
Phosphorylation of MLC2 at Ser19 followed by Thr18 enhances the ATPase activity of myosin 
II, promoting its interaction with actin filaments and thereby increasing cell contractility (54). 
The penetration of pre-existing ECM by amoeboid tumor cells without proteolysis requires 
sufficient motive force and cell tension. The intracellular pressure leads either to detachment 
from the matrix or to the formation of membrane blebs. The formation of blebs is driven by 
inflow of the cytoplasm and not by the actin polymerization that leads to lamellipodia in 
mesenchymal motility (55).  
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Figure 8. Interactions between the components of signaling pathways 
documented to be involved in the MAT/AMT transitions of cells in a 3D 
environment. The inhibition of the activity of the proteins highlighted in red was 
shown to trigger amoeboid to mesenchymal transitions. Inactivation of the 
proteins depicted in green induces a conversion from the mesenchymal to the 
amoeboid mode of invasiveness. Solid lines direct connections, dashed lines 
indirect connections. (Taken from (32)). 
1.2.3  Collective motility 
In contrast to single-cell migration, collective motility of tumor cells involves the movement of 
whole clusters, sheets or strands, a process that often occurs during embryogenesis and the 
development of mammalian glands (56-58). Of the variants of collective migration shown in 
Figure 5, “cluster/cohorts” are detached and disseminating cell collectives, such as those 
observed in the highly differentiated epithelial cancers of breast and colon. “Multicellular 
strands/sheets” do not detach or metastasize. However, these cells still have invasive features 
(33). Collective invasion is characterized by a high concentration of autocrine growth factors and 
proteolytic enzymes that promote tumor growth and invasion.  
 
1.2.4  Switching between modes of motility 
In in vitro and in vivo 
studies, an MMP inhibitor 
cocktail treatment induced the 
transition to a typical amoeboid 
rounded morphology, 
indicating the compensatory 
nature of invasion by tumor 
cells (43). In addition, 
inhibition of integrin activity 
was also shown to promote 
Collective Amoeboid 
Transition (CAT) (59). Since amoeboid invasion largely relies on Rho/ROCK signaling 
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pathways, suppression of either Rho or ROCK will trigger a transition from a rounded 
morphology to an elongated mesenchymal shape (46). Rac1-mediated cell polarity and 
lamellipodia formation are believed to be the key regulators of mesenchymal invasion. Inhibition 
of Rac impairs the assembly of focal adhesion and therefore renders the amoeboid motility (60).   
Smurf1 protein is an E3-ubiquitin ligase that degrades RhoA and impairs Rho/ROCK 
signaling (61). Inhibition of Smurf1 in mesenchymal BE colon cells is sufficient to induce MAT 
(62). Additionally, p53 was reported to act downstream of cdc42, which is involved in many 
pathways important in the regulation of cell motility. The loss of p53 activity can trigger MAT 
along with increased RhoA activity (63). The components of the signaling pathways involved in 
MAT/AMT are illustrated in Figure 8.  
 
1.3  The Tyro3/Axl/Mer receptor tyrosine kinase family 
The human genome encodes 90 tyrosine kinases that modulate a wide range of fundamental 
cellular events, including proliferation, growth, metabolism, apoptosis and motility (64). The 58 
RTKs are classified into 20 families that transduce signals from the extracellular environment to 
the cytoplasm and nucleus by binding to ligands. TAM receptor tyrosine kinase family members 
are among the few that are specific to vertebrates (65). TAM receptors are characterized by a 
conserved sequence KW(I/L)A(I/L)ES within the kinase domain, as well as two fibronectin type 
III repeats and two immunoglobulin-like domains in the extracellular region (66) (Fig. 9). 
Overall, the protein sequences of the human TAM receptors within the kinase domain are 54-
59% identical (72-75% similar), while the protein sequences in the extracellular domain are 31-
36% identical (52-57% similar) (67). The predicted molecular weights of TAM receptors are 97, 
98 and 110 kDa, respectively. However, the actual sizes range from 100 to 140 kDa for Axl and 
Introduction  
14 
 
Figure 9. Schematic of TAM receptors and their ligands protein S and Gas6. a, The domain structure of TAM receptor 
family. b, The two TAM receptor ligands, Protein S and Gas6, also share a common domain structure. c, Binding of the 
ligand to the two immunoglobulin domains of the receptor is mediated via the LG1 region of the ligand. (Taken from 
(122)). 
Tyro3 and 165-205 kDa for MerTK due to posttranslational modifications, especially 
glycosylation (68-70). Tyro3 and Axl are ubiquitously expressed in tissues, whilst MerTK is 
mainly expressed in the hematopoietic system (66). High expression of MerTK is also found in 
ovary, prostate, testis, lung, retina, and kidney. Lower levels of MerTK are found in heart, brain, 
and skeletal muscle (66). In addition, TAM receptors are markedly expressed in many cancer 
types (Table 3).  
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Table 3. TAM receptors expression in human cancers 
Cancer Axl Mer Tyro3 
Myeloid leukemias (AML, CML) (71-74)  (75) 
Lymphoid leukemias (ALL)  (76-78)  
Erythroid leukemia (72)   
Megakaryocytic leukemia (72)   
Mantle cell lymphoma  (79)  
Multiple Myeloma   (80) 
Uterine endometrial cancer (81)  (81) 
Gastric cancer (82, 83) (83)  
Colon cancer (84)   
Prostate cancer (85-87) (88)  
Thyroid cancer (89-91)  (91) 
Lung cancer (92, 93)   
Breast cancer (94, 95) (96)  
Ovarian cancer (97-99)   
Liver cancer (100)   
Renal cell carcinoma (101)   
Astrocytoma/Glioblastoma (102-104) (5, 104)  
Pituitary adenoma  (105)  
Melanoma (106-108) (108, 109) (108) 
Osteosarcoma (110)   
Rhabdomyosarcoma  (111)  
Pancreatic cancer (112, 113)   
Bladder cancer (114, 115)   
Hepatocellular carcinoma (116, 117)   
Oral squamous cell carcinoma (118)   
 
 
 
Introduction  
16 
 
Figure 10. Overall architecture of the Gas6-LG/Axl-IG complex. 
Shown are three orthogonal views. A. Top view, towards the cell 
membrane harboring the receptor. B. Side view, with the cell 
membrane at the bottom. C. Front view, in the direction 
indicated by the arrow in (B). Surface representations are shown 
in (A) and (B), while a cartoon representation is shown in (C). 
Gas6-LG is in cyan (N-terminal segment and LG1) and green 
(LG2), Axl-IG is in yellow (IG1) and brown (IG2). In (C), the 
Gas6-LG molecule at the back has been removed for clarity, a 
calcium ion in the LG1-LG2 interface is shown as a pink sphere, 
and the Gas6/Axl contact sites are labeled. (Taken from (124)). 
Regulation of TAM-TK activity  
The reported biological ligands of TAM receptors are vitamin K-dependent Gas6, Protein S, 
Tubby and Tubby-like protein 1 (Tulp1) (119-121). Gas6 and protein S share 43% protein 
sequence identity and have the same 
structure with an N-terminal Gla domain 
(a region which is γ-carboxylated in a 
vitamin-D-dependent posttranslational 
modification), four epidermal growth 
factor (EGF)-like domains and two 
laminin-G (LG) domains. Thrombin 
cleavage sites are present in Protein S but 
not in Gas6 (122) (Fig. 10B). Although 
Gas6 binds to and activates all TAM 
receptors, MerTK has the lowest binding 
affinity for Gas6 (120). The newly identified ligand Tupl1 can bind to all three TAM members, 
while Tubby binds only to MerTK (121). Protein S was first described as a ligand of Tyro3 (123). 
Nevertheless, the validity of Protein S as a ligand of all TAM receptors requires further 
investigation (66). The crystal structure of the Gas6/Axl complex reveals an assembly of 2:2 
stoichiometry, in which the two Ig-like domains of the Axl are crosslinked by the LG1 domain of 
Gas6, with no direct Axl/Axl or Gas6/Gas6 contacts (124) (Fig. 10). There are two distinctive 
Gas6/Axl binding sites that are required for Axl activation. However, only the minor Gas6 
binding site is conserved in MerTK and Tyro3, indicating that the structures of the Gas6/MerTK 
and Gas6/Tyro3 complexes may be very different (124).  
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Conventional RTK activation is believed to be initiated by ligand binding to the extracellular 
domain, which leads to the trans-autophosphorylation of multiple tyrosine residues within the 
kinase domain and further to downstream signaling (125). In relation to this, five possible means 
of TAM receptor activation have been proposed: 1. ligand-independent dimerization; 2. ligand-
dependent dimerization; 3. heteromeric dimerization of two different TAM receptors; 4. 
heterotypic dimerization with a non-TAM receptor; 5. trans-cellular binding of extracellular 
domains (66).  
Full activation of MerTK requires the autophosphorylation of Y749, Y753 and Y754 in the 
activation loop of the kinase domain (126). Further in vitro kinase assays have identified tyrosine 
749 as the preferred site of autophosphorylation, and single mutations of the three residues to 
phenylalanine reduced MerTK kinase activity to 39%, 10% and <6%, respectively (126). These 
three tyrosine residues are conserved in TAM receptors and correspond to residues Y681, Y685 
and Y686 in human Tyro3 and residues Y698, Y702 and Y703 in human Axl. Interestingly, 
autophosphorylation of Tyro3 and Axl at these sites has not been reported (66). 
The tight control of protein kinases maintains normal cellular functions, and aberrant 
expression or dysfunction of tyrosine kinases is responsible for many diseases, including cancers. 
In this connection, several counter-reactions have developed that attenuate or terminate tyrosine 
kinase activities induced by the stimulation of ligands, including antagonistic ligands, hetero-
oligomerization with receptor inactive mutants, phosphorylation of inhibitory residues by other 
kinases, dephosphorylation of activating residues by phosphatases and receptor endocytosis, and 
degradation (125). Only a few of these mechanisms have been reported in the case of TAM 
receptor deactivation. Although the phosphatase C1-TEN was shown to bind Axl, neither 
enzymatic activity of C1-TEN nor direct dephosphorylation of Axl have been demonstrated 
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(127). Soluble forms of Axl and MerTK, produced by proteolytic cleavage were detected in 
murine and human plasma (70, 128-130). Binding of soluble Axl or MerTK to Gas6 can block 
the normal cellular functions of full-length kinases (70, 128).  
 
Cellular functions of TAM-TKs 
The activation of TAM receptors has diverse cellular effects depending on cell type and the 
microenvironment. Mice with single, double or even triple TAM member knockout are viable 
(68, 131, 132). However, TAM adult knockout mice develop autoimmune diseases, including 
rheumatoid arthritis and lupus (131, 133). The phenotype is more pronounced in double than 
single knockouts and most severe in triple knockouts, suggesting overlapping or cooperative 
roles of TAM receptors (131). Further investigation found these symptoms to be associated with 
a deficiency of apoptotic cell clearance by macrophage and dendritic cells (132).  
Clearance of apoptotic cells plays an important role in the maintenance of normal cell 
function. Progressive accumulation of cell debris increases tissue necrosis, leading to 
inflammation and autoimmune diseases. Phosphatidylserine (PS) receptors expressed on the 
surface of apoptotic cells were shown to bind directly to phagocytes or indirectly to soluble 
proteins, including Gas6 and Protein S, which suggests that TAM receptors recognize apoptotic 
cells through their ligands (134, 135). The newly identified TAM receptor ligands Tubby and 
Tulp1 are bridging molecules, with their N-terminal regions binding to MerTK and the C-
terminal regions interacting with apoptotic cells (121). Further study showed MerTK to be 
involved mainly in macrophage-mediated clearance while dendrite clearance of apoptotic cells 
was mostly regulated by Axl and Tyro3 (136). TAM receptors have also been shown to regulate 
mammalian spermatogenesis (68). Male animals lacking all three TAM receptors are infertile 
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and have smaller testes than wild-type males (68). About 1 week after the onset of sperm 
production, the seminiferous tubes of the testes of TAM
-/-
 mice are full of apoptotic cell debris, 
resulting in the death of nearly all germ cells. This degenerative phenotype is due to the lack of 
functional TAM receptors in Sertoli cells, which express all three TAM receptors and their 
ligands (68). Without TAM signaling, clearance of apoptotic germ cells in the testes is almost 
completely abolished (68, 137-139).  
A remarkably similar phenotype is observed in the retina of TAM knockouts. In this situation, 
MerTK is seemed to make the major contribution (140). Adult MerTK knockouts are blind due 
to the rapid and progressive degeneration of photoreceptors (PRs) (141). This is a degenerative 
rather than a developmental phenotype as the retina of MerTK knockouts develop normally and 
at 2 weeks after birth are still histologically indistinguishable from wide-type. However, around 
3 weeks after birth, apoptotic cells are seen specifically in the PR layer of MerTK knockouts, and 
by 10 weeks nearly all the PR cells have died (141). In agreement with this, mutation of MerTK 
was found in retinal dystrophic Royal College of Surgeons (RCS) rats and in patients with 
retinitis pigmentosa (142, 143). Later, co-immunoprecipitation identified an interaction between 
MerTK and myosin IIA heavy chain. Treating MerTK
+/+
 retinal pigment epithelial cells (RPEs) 
with photoreceptor outer segment (OS) tips led to the redistribution of myosin IIA and IIB from 
the cell periphery to co-localize with ingested OS, which consequently facilitated phagocytosis. 
In contrast, MerTK
-/-
 RPEs failed to regulate myosin II redistribution and exhibited a severe 
phagocytic defect (144). Consistently, MerTK
-/-
 mice have considerably more antibody-forming 
cells (AFCs) and germinal centers (GCs) than wild type, as well as Th1-skewed IgG2 antibody 
responses against the T cell-dependent antigen (145). MerTK is expressed by tangible body 
macrophages (TBM Φs) in GCs, which contain many phagocytized apoptotic cells in various 
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states of degradation. MerTK
-/-
 mice have more apoptotic cells in GCs than MerTK
+/+
 mice, 
whereas the number of TBM Φs is similar, suggesting an important role for MerTK in GC 
apoptotic cell clearance by TBM Φs, as well as in the regulation of B cell tolerance operative in 
the AFC and GC pathways (145).  
In addition to playing a crucial role in apoptotic cell clearance, TAM receptors have been 
shown to regulate innate immune responses. MerTK knockout mice produce TNF-α in excess 
upon lipopolysaccharide (LPS) administration with an associated increased sensitivity to LPS-
induced endotoxic shock (146). Moreover, TAM receptors were shown to be negative regulators 
of both Toll-like receptor (TLR) and TLR-induced cytokine receptor cascades through the type I 
interferon receptor (IFNAR) and its associated transcription factor STAT1(147). TLR induction 
of IFNAR-STAT1 signaling upregulates TAM signaling and hijacks this pro-inflammatory 
pathway by inducing the cytokine and TLR suppressors SOCS1 and SOCS3 (147). MerTK can 
also prevent autoimmune diseases by negatively regulating hematopoietic cell migration into the 
peritoneal cavity, whilst cells lacking other TAM members, Axl or Tyro3, do not show aberrant 
regulation in peritoneal cell numbers or the autoimmune phenotype (148). Further study 
identified elevated expression of CXCL9, its receptor CXCR3, and IL-7R on MerTK
-/-
 peritoneal 
cells. Deletion of CXCR3 donor cells decreased the number of adoptively transferred cells that 
entered into the peritoneum of MerTK-/- mice (148).  
Furthermore, MerTK knockout mice are more vulnerable to Nephrotoxic serum (NTS) 
treatment, with a decreased survival rate and significantly increased proteinuria and serum urea 
levels compared with wild type at day 3 post-injection (149). Upon NTS treatment, MerTK 
expression is significantly increased in glomeruli in WT mice, whilst MerTK
-/-
 glomeruli are 
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Figure 11. Tyro‐3 signaling pathways mediate platelet aggregation, cell transformation, and 
osteoclastic bone resorption. Molecules in blue have been shown to associate with Tyro‐3 
through either a direct or indirect interaction. Phosphorylation of Tyro‐3 at specific residues 
remains uncharacterized. (Taken from (66)). 
hyperplastic and later become necrotic (149). The protective role of MerTK seen in NTS-induced 
nephritis may arise through its activity in apoptotic cell clearance and anti-inflammation.  
In addition, Gas6-/- mice and TAM single knockouts display platelet dysfunction, predicting 
that all TAM members are required for platelet aggregation (134, 150). Not surprisingly, TAM 
double or triple knockouts exhibit a more severe phenotype than single knockouts, with impaired 
hemostasis and
 
mild thrombocytopenia (151). 
In summary, TAM members and their ligands play essential roles in apoptotic cell clearance 
and innate immune response. However, it is not yet known whether the specificity of TAM 
signaling in phagocytosis is associated with other factors, such as the specific process leading to 
the death of the apoptotic cells. 
 
1.3.1 Tyro3 signaling 
Tyro3 is the 
least-studied of the 
TAM receptors and 
the downstream 
signaling pathways 
of Tyro3 are poorly 
characterized. The 
molecules known to 
be involved in 
Tyro3 signaling are illustrated in Figure 11. Co-immunoprecipitation of Tyro3 transiently 
expressed in COS-7 cells revealed a potential interaction with Src kinase family members (152). 
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Due to the cross-reactivity of the Src antibody used, it is still not clear with which Src kinase 
member the Tyro3 interacts: Src, Fyn or Yes. It is very interesting that all Src family members 
are highly expressed in the central nervous system, where Tyro3 is also expressed. Ran-binding 
protein in the microtubulin organizing center (RanBPM) and PI3K subunit p85 were identified as 
interaction partners of Tyro3 by yeast two-hybrid studies (153, 154). The expression of 
EGFR/Tyro3 (a fusion receptor with the extracellular domain of EGFR and the transmembrane 
and intracellular domains of Tyro3) transformed NIH3T3 cells upon EGF treatment through the 
activation of PKB. Treatment with the PI3K inhibitor Wortmannin effectively diminished PKB 
phosphorylation and inhibited anchorage-independent colony formation, indicating that the 
oncogenic function of Tryo3 is to some extent mediated by the PI3K/PKB signaling cascade 
(153). Phosphorylation of MAPK was upregulated in parental 293 cells in response to Gas6 
treatment, which linked Tyro3 to MAPK signaling pathways (119). Gas6-induced Tyro3 
phosphorylation was enough to activate MAPK signaling in mouse osteoclasts, resulting in bone 
resorption (155). Protein S/Tyro3 inhibits oxygen/glucose deprivation-induced BBB breakdown 
through the activation of sphingosine 1-phosphate receptor (S1P1), leading to Rac1-dependent 
BBB protection (156). RNA interference studies have excluded the involvement of Axl or 
MerTK in the maintenance of BBB integrity, revealing the distinctive function of TAM receptors 
in this physiological context. Therefore, the role of Tyro3 and the mechanism of Tyro3 activation 
need to be defined further.  
 
1.3.2 Axl signaling 
Axl was the most intensively studied TAM receptor of the past few years. Overexpression of 
a chimeric receptor EGFR/Axl with the extracellular domain of EGFR and the transmembrane 
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Figure 12. Axl signaling pathways. Molecules in blue have been shown to associate with Axl through either a direct or 
indirect interaction. Tyrosines 779, 821, and 866 of Axl are phosphorylated (yellow circles) and mediate interactions 
with a number of signaling molecules. Amino acid designations are from the human sequences. (Taken from (66)). 
and intracellular domains of Axl promoted 32D cell survival and mitogenesis by activating 
MAPK signaling pathways upon EGF treatment (157). In this situation, EGFR/Axl chimeric 
receptor associated with adaptor proteins Grb2 and Shc as well as PI3K subunit p85 in a ligand-
dependent manner (157). Furthermore, tyrosine 821 was identified as the docking site for 
multiple effectors, including not only p85 and Grb2, but also PLC-γ, c-src and lck (158). 
Tyrosine 779 exhibited a lower binding affinity for p85 than tyrosine 821, and tyrosine 866 was 
an additional docking site for PLC-γ (158). Surprisingly, Gas6-stimulated cells did not exhibit 
inhibition of apoptosis or a mitogenic response, which is correlated with the absence of Ras/ERK 
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activation. This suggests that different extracellular domains substantially altered the 
intracellular response of Axl kinase (157).  
It is also very clear that Axl binding to and activation of PI3K are important events linked to 
multiple downstream pathways, including survival, proliferation and migration. In NIH3T3 cells, 
activation of Axl upon Gas6 treatment prevents apoptosis of cells after complete growth factor 
removal via the recruitment of p85 and subsequent activation of PI3K downstream targets PKB 
and S6K (159). In addition, Src kinase activity was also shown to be required for the survival 
effect of Gas6 (159). Gas6 stimulation protects cells from apoptosis through PKB-mediated 
BAD phosphorylation in serum-starved NIH3T3 cells (160). Nuclear NF-κB binding activity is 
increased upon Gas6 treatment associated with upregulation of Bcl-xL, thus promoting cell 
survival. In this study, p105 was identified as a substrate of GSK3β, which is phosphorylated 
upon Gas6 treatment leading to its downregulation (161). In endothelial cells, Gas6 treatment 
promotes another Gas6/Axl-induced survival pathway involved in PI3K-mediated activation of 
the Rho family, Rac and Rho, as well as downstream kinases Pak, JNK/SAPK and p38 MAPK 
(162). While many early experiments were conducted in NIH3T3 cells expressing all three TAM 
receptors, Axl
-/-
 fibroblasts show high levels of serum-deprivation-induced apoptosis that cannot 
be rescued by addition of Gas6, indicating that Axl is the main factor in Gas6/PI3K/PKB-
mediated survival (163). Constitutively activated Axl is found in lymphocytic leukemia and 
correlates with the activation of PI3K, Lyn, and ZAP70, as well as PLC γ2 (164). 
Gas6/Axl signaling is also involved in many other cellular functions, such as migration, 
cytokine production and proliferation. Axl is expressed by migratory but not post-migratory 
Gonadotropin-releasing hormone (GnRH) neurons. Binding to Gas6 promotes cytoskeletal 
remodeling and migration through the Rho family GTPase Rac and p38MAPK (165). In these 
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cells, Gas6-induced lamellipodia formation and motility is through the association of Axl with 
PI3K subunit p85, and this phenomenon is blocked after PI3K inhibition. In addition, PI3K 
suppression in GnRH neurons mitigated Gas6-induced Rac activation, suggesting that the PI3K 
pathway is the major mediator of Axl action upstream of Rac, promoting GnRH neuronal cell 
migration (166). In addition, Axl plays a role in the anti-inflammatory effects of type I IFNs. 
Activation of Axl leads to increased Twist expression and decreased TNFα production (167). 
Twist proteins (Twist1 and Twist2) are basic helix-loop-helix (bHLH) transcriptional repressors 
that bind to E boxes within the TNFα gene promoter and repress NF-κB-mediated TNFα 
transcription (167). Given that Protein S stimulation also induces Twist upregulation as well as 
TNFα reduction, MerTK and Tyro3 may also be implicated in the regulation of Twist expression 
and TNFα production. Moreover, Gas6/Axl has been shown to promote Mesangial cell 
proliferation through the positive regulation of STAT3 phosphorylation and transcriptional 
activity (168).  
 
1.3.3 MerTK signaling 
MerTK was first identified in the form of the chicken proto-oncogene c-eyk expressed in 
embryonic chicken brain, which was derived from the chicken retrovirus RLP30 (169, 170). 
Human MerTK was cloned from a human B-lymphoblastoid Agt11 expression library and 
named after its predominant expression in monocytes, epithelial and reproductive tissues (76). 
Early studies using a chimeric receptor composed of the extracellular domain of the human 
colony-stimulating factor 1 receptor (Fms) and the transmembrane and cytoplasmic domains of 
human MerTK showed that MerTK is linked to PI3K/PKB, PLCγ, and MAPK/ERK signaling 
(Figure 13). Ligand stimulation of Fms-MerTK-expressing NIH3T3 cells led to cellular 
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Figure 13. Mer signaling pathways lead to platelet aggregation, cell survival, regulation of proinflammatory cytokine 
production, and regulation of the actin cytoskeleton. Molecules in blue have been shown to associate with Mer through 
either a direct or indirect interaction. Tyrosines 749, 753, and 754 (yellow circles) within the Mer kinase domain are sites 
of autophosphorylation. Ub: ubiquitin. (Taken from (66)). 
transformation and increased proliferation (171). Gas6 was later identified as a ligand for MerTK 
that could rapidly induce MerTK phosphorylation and consequently activate the MAPK 
signaling pathway (119). In addition, clearance of apoptotic lymphocytes by macrophage 
requires the activation of MerTK, in part via association of PLCγ2 with MerTK, and tyrosine 
phosphorylation of PLCγ2 (172). Further studies revealed that the tolerogenic phenotype 
displayed by dendritic cells or macrophages upon exposure to immunogens, such as apoptotic 
cells and LPS, is mainly due to inhibition of NF-κB mediated by the MerTK/PI3K/PKB pathway 
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(173, 174). The multiple MerTK downstream targets may act independently or in parallel 
according to cell type and tissue microenvironment. Convergent activation of different 
downstream signaling components by an EGFR-Mer chimeric receptor, including PKB, ERK1/2, 
and p38 MAPK, resulted in reduced apoptosis without affecting proliferation (175). Nevertheless, 
PI3K/PKB and MAPK/ERK are reported to be counteractive when Fms-MerTK is overexpressed 
in prostate cancer cell lines. Activation of MerTK leads to the upregulation of IL-8 through the 
nuclear accumulation of transcriptional factors c-Jun and c-Fos that bind to the AP-1 promoter 
region. Inhibition of MEK attenuated ERK activity and reduced IL-8 production, whilst 
treatment with a PI3K inhibitor did not, indicating that MerTK-induced IL-8 expression is 
mainly via the MEK/ERK pathway (88). However, in human macrophages, Protein S-induced 
MerTK activation suppressed the expression of macrophage scavenger receptor A (SR-A) at both 
the mRNA and protein levels by preventing binding of transcriptional factors to the AP-1 
promoter element (176). Collectively, further work is needed to elucidate the myriad signaling 
pathways regulated by MerTK.  
MerTK has also been reported to promote cell survival via atypical signaling pathways. 
Activated Cdc42-associated kinase (Ack1), an intracellular tyrosine kinase, was identified as a 
phosphoprotein that responded to MerTK activation upon Gas6 treatment (177). Association of 
MerTK and Ack1 was detected by co-immunoprecipitation of the endogenous proteins in a 
phosphotyrosine-dependent manner following Gas6 stimulation. Expression of wild-type, kinase 
dead and constitutively active Ack1 demonstrated that Ack1 is not a direct substrate of MerTK. 
However, autophosphorylation of Ack1 is significantly increased by activation of MerTK. The 
maintenance of Ack1 activity requires an interaction with heat shock protein 90β (Hsp90β). 
Furthermore, mass spectrometry analysis of constitutively active Ack1 immunoprecipitates also 
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identified the tumor suppressor Wwox as an interaction partner. Ack1 tyrosine phosphorylates 
Wwox predominantly at Y287 and induces its ubiquitination and degradation, demonstrating that 
MerTK-mediated Ack1 activation promotes anchorage-independent growth, and tumor growth in 
vivo may be due to the downregulation of pro-apoptotic tumor suppressor Wwox.  
In addition to its involvement in proliferation and survival regulated by well-known signaling 
pathways like PI3K/PKB, MAPK/ERK, and PLCγ, MerTK has been studied in the regulation of 
the actin cytoskeleton. In yeast two-hybrid assays, the guanine nucleotide-exchange factor (GEF) 
VAV1 was found to interact with MerTK through its SH2 domain (178). Activation of MerTK 
resulted in tyrosine phosphorylation of Vav1 and release from MerTK, followed by GDP/GTP 
exchange on Rac1 and cdc42. Further study using Gas6 to stimulate primary 
monocytes/macrophages disclosed Rac1 and cdc42 activation and this potentially explains how 
MerTK precisely coordinates cytoskeletal changes that govern the ingestion of apoptotic material 
by macrophages and pigmented retinal epithelial cells. Furthermore, activation of MerTK 
induced Src-mediated tyrosine phosphorylation of FAK on Tyr
861
, recruitment of FAK
 
to the 
αvβ5 integrin, and formation of a p130CAS/CrkII/Dock180 complex, and consequently activated 
Rac1 (179). The expression of phosphatidylserine (PS) on the outer surface of the apoptotic cell 
provides an “eat-me” signal recognized by phagocytes either directly via PS receptor (PS-R) or 
indirectly via αvβ5(3) integrin or TAM kinases (180, 181). Co-expression of MerTK with αvβ5 
integrin led to Rac1 activation, lamellipodial formation and the phagocytosis of apoptotic cells. 
Interestingly, treatment with Gas6 or the expression of constitutively active MerTK failed to 
stimulate p130
CAS
 tyrosine phosphorylation or phagocytosis in β5-deficient or in mutant β5ΔC-
expressing cells, indicating that functional MerTK is linked to the integrin pathway (179).  
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MerTK has been shown to cross-talk with other receptor tyrosine kinase pathways. A431 
cells were employed to perform a large-scale functional analysis of EGF-induced pathway 
activation. RNA interference targeting MerTK in EGF-treated cells mitigated ERK and STAT3 
phosphorylation. Notably, MerTK was found to be required for surface accumulation of EGFR 
and subsequent pathway activation (182).  
 
1.3.4 Dysregulation of TAM-TKs in cancers 
As shown in Table 3, overexpression of TAM receptors is associated with the development 
of many cancers, being involved in migration and invasion, angiogenesis, cell survival and tumor 
growth. Each known TAM family member was cloned originally from cancer cells and early 
studies demonstrated that these RTKs were able to transform 32D and NIH3T3 cells as well as 
BaF3 lymphocytes (69, 153, 171, 183, 184).  
 
Malignant gliomas 
The TAM receptor tyrosine kinases have recently been implicated in glioma cell growth, 
invasion, and chemoresistance. Upregulation of Axl and Gas6 is found in GBM cell lines and 
gliomas of malignancy grades WHO III and IV (102, 103). Overexpression of a dominant-
negative Axl mutant was shown to suppress brain tumor growth and resulted in long-term 
survival of mice after intracerebral glioma cell implantation, in contrast to cells expressing Axl 
wild type (102). Detailed functional analysis revealed that inhibition of Axl signaling interferes 
with tumor cell proliferation, migration and invasion (102). Comparative immunohistological 
studies have demonstrated that Axl staining is most pronounced in glioma cells of 
pseudopalisades and reactive astrocytes. In addition, co-expression of Axl and Gas6 was 
Introduction  
30 
 
observed in glioma cells and tumor vessels, predicting a potential activity of Gas6/Axl signaling 
in tumor angiogenesis. Interestingly, Axl was not detected in non-neoplastic brain tissue, while 
Gas6 is highly expressed in neurons. GBM patients with either high expression of Axl or co-
expression of Axl and Gas6 exhibited a substantially shorter lag to tumor progression and a 
poorer overall survival (103). More recent investigations show that knockdown of either Axl or 
MerTK leads to increased apoptosis of astrocytoma cells and a substantial decrease in cell 
proliferation in soft agar. Moreover, suppression of Axl and MerTK significantly improved 
chemosensitivity in astrocytoma cells upon temozolomide, carboplatin, and vincristine treatment 
(185). Overall, continuing investigation of the function and mechanism of TAM kinases in 
gliomas will be valuable, not only helping with the deciphering of gliomagenesis but also 
potentially providing novel targets for drug discovery.  
 
Hematopoietic cancers 
Blood cancer, including lymphoma, leukemia and myeloma, is one of the most life-
threatening diseases. The molecular characterization of normal and malignant blood cells and 
their genetic and molecular abnormalities in particular blood cancers has led to new targeted 
drugs that selectively kill cancer cells, generally sparing normal cells and causing fewer side-
effects than previous standard therapies. High expression and phosphorylation of Axl and 
MerTK were first identified in blood cancers (69, 76). The expression of Axl in a 32D myeloid 
cell line resulted in aggregation dependent on Gas6 treatment, suggesting an important function 
for Gas6/Axl signaling in the mediation of cell-cell binding and cell adhesion (186). Axl 
expression was further investigated in patients with acute myeloid leukemia (AML) and found to 
be associated with very poor overall survival (71). Further studies found that Axl is induced by 
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chemotherapy drugs and overexpression of Axl in myeloid leukemia cells confers drug resistance 
in AML. Treatment of Axl-expressing U937 cells with Gas6 not only led to activation of survival 
signaling pathways but also increased the expression of Bcl-2 and Twist (187). MerTK is not 
expressed in normal lymphocytes or thymocytes; however, aberrant MerTK mRNA transcripts 
and protein expression are found in acute lymphoblastic leukemia (ALL) cell lines and patients 
(188). MerTK transgenic mice were generated by expressing MerTK in the hematopoietic 
lineage under control of the Vav promoter. At ages of 12-24 months, over 55% of MerTK 
transgenic mice developed adenopathy, hepatosplenomegaly, and circulating lymphoblasts 
compared with 12% of the wild type. A significant survival improvement was observed in 
MerTK transgenic lymphocytes compared with wild-type lymphocytes upon dexamethasone 
treatment, indicating that MerTK plays a role in leukemogenesis (188). Inhibition of MerTK 
sensitizes B-ALL cells to apoptosis induced by cytotoxic reagents in vitro and delays disease 
onset in a mouse model of leukemia (189). Given the fact that leukemia cells can spread to all 
organs via the bloodstream and lymph vessels, radio/chemotherapy instead of surgery is 
commonly used to destroy cancer cells, concomitant with the known severe side-effects. In this 
situation, a comprehensive understanding of the genetic alterations and the identification of 
more-specific therapeutic targets are desperately needed. Taken together, ongoing research to 
dissect the mechanisms of TAM receptors in blood cancers may provide attractive targets for 
biologically based leukemia/lymphoma treatment.  
 
Melanoma 
Melanoma is a form of cancer that begins in melanocytes and it is the leading cause of death 
from skin disease. The National Cancer Institute at the National Institutes of Health has 
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estimated that the new cases from melanoma will rise to 70,230 and cause 8,790 deaths in 2011 
in the USA. The standard treatment for melanoma is surgical removal of the cancerous cells and 
some normal tissue surrounding the neoplastic area, followed by radio/chemotherapy. In recent 
decades, targeted cancer therapies based on studies of molecular and cellular changes specific to 
cancer are becoming more effective than conventional treatments, and less harmful to normal 
cells. A series of microarray analyses has identified upregulation of all three TAM receptors in 
different subtypes of melanomas (109, 190, 191). Although the role of MerTK in melanoma 
oncogenesis is still poorly understood, Tyro3 is reported to be an upstream regulator of 
Microphthalmia-associated transcription factor (MITF) (191). MITF is a master gene mediating 
melanoma development and acts as a “lineage addiction” oncogene in malignant melanoma. 
MITF expression is induced upon activation of Tyro3 in a SOX10-dependent manner. In human 
primary melanoma tissues, high expression of Tyro3 is correlated with MITF mRNA levels. 
Depletion of Tyro3 inhibits cell proliferation and colony formation in melanoma cells and 
increases chemotherapeutic agent-induced apoptosis. In vivo, knockdown of Tyro3 in melanoma 
cells also prevented tumorigenesis (191). Interestingly, Axl has been shown to be highly 
expressed in MITF-negative melanoma tissues, demonstrating the diversity of TAM receptor-
mediated signaling pathways in melanoma (192). In addition, melanoma cell motility is 
significantly inhibited in vitro by Axl knockdown. Expression of an antisense construct of Axl in 
Mel 290 melanoma cells resulted in downregulation of Cyr61, a member of the CCN (cyr61, ctgf, 
nov) proteins involved in tumor progression (107). Axl is also known to be positively correlated 
to PKB phosphorylation accompanied by weak TUNEL staining in squamous cell carcinoma 
tumors. Whilst knockdown of Axl did not affect cell proliferation, it sensitized cells to UV-
induced apoptosis through activation of Bad, a change in the conformation of the Bax and Bak, 
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release of cytochrome c into the cytosol, and activation of caspases (193). Altogether, exploring 
the distinctive activity of TAM receptors in melanoma oncogenesis opens up an interesting 
research area, and selectively targeting TAM members may be an effective therapeutic strategy 
for specific types of skin cancers.  
 
Breast cancer 
Breast cancer starts most commonly from the ducts that transport milk from the breast to the 
nipple or from the lobules that produce milk. While it occurs in both men and women, the 
overwhelming majority of cases in humans occur in women. Standard treatments for breast 
cancer include surgery, radio/chemotherapy and endocrine therapy. The receptor status, such as 
the presence or absence of estrogen receptor (ER), progesterone receptor (PR) and HER2 within 
the tumor cells, is commonly used to guide treatment selection. Tumors positive for hormone 
receptors respond to endocrine therapy with a good prognosis. The outcome of another 20% of 
HER2 positive tumors significantly improves on receipt of the anti-HER2 monoclonal antibody 
Trastuzumab or the HER2 small-molecule inhibitor Lapatinib. Nevertheless, subsets of breast 
cancer are quite resistant to treatment options and prognosis is discouraging. For example, as 
many as 11-20% of breast cancers are negative for ER, PR or HER2 (194). Despite an increased 
sensitivity to standard cytotoxic chemotherapy reagents, triple-negative breast cancers carry an 
unfavorable prognosis. Thus, there is a pressing need to identify the mechanisms of resistance 
and those driving kinases in these tumors in order to develop more efficient therapeutic 
interventions.  
High expression of Axl is positively correlated with advanced tumor stages in breast cancer 
patients (94, 95). Silencing Axl completely prevents the metastasis of breast carcinoma cells 
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from the mammary gland to lymph nodes and several organs, which substantially improves 
overall survival (195). Axl is strongly induced by overexpression of vimentin, an important EMT 
marker facilitating mesenchymal cell migration. Activated Axl elicits a positive feedback loop 
that further promotes vimentin-mediated cell migration. In vivo, Axl actively contributes to lung 
extravasation of breast cancer cells in mice (196). In solid cancer cell lines, including breast 
cancer, NSCLC (non-small cell lung cancer) and colorectal cancer (CRC), Axl expression is also 
shown to be regulated by miR-34a and miR-199a/b by targeting its 3’-UTR (196). In breast 
cancer cells, activation of Axl enhances the expression of MMP-9, facilitating Axl-mediated 
invasion both in vitro and in vivo (197). Overexpression of Axl leads to NF-κB transactivation 
and brahma-related gene-1 (Brg-1) translocation through activation of ERK signaling. MMP-9 
activation was strikingly blocked by the inhibition of ERK signaling or overexpression of the 
dominant negative mutant IκB and Brg-1 (197). Additionally, Axl has been identified as a novel 
regulator of endothelial cell migration towards the matrix factor vitronectin. Knockdown of Axl 
in metastatic breast cancer cell line MDA-MB-231 significantly impeded angiogenesis in vivo 
(198, 199). Interestingly, expression of Axl and ER are positively associated and the Gas6 
promoter is directly regulated by ER, suggesting a potential role for Gas6/Axl signaling in ER
+
 
breast cancer progression (94, 200). Gas6 has also been shown to be highly expressed in PR-B-
positive breast cancer tissues and upregulation of Gas6 mRNA was observed in PR-B- but not in 
PR-A expressing cells (201, 202). Notably, MerTK is highly expressed in lung metastatic MDA-
MB-231 cells inversely regulated by miR-335. Inhibition of miR335 in parental MDA-MB-231 
cells enhances MerTK expression and may further promote metastasis (96). Undoubtedly, the 
activity of MerTK in breast cancer metastasis requires further investigation. Nevertheless, these 
findings already suggest a novel route for metastatic breast cancer treatment.  
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TAM receptor inhibition in cancer treatment 
Targeted therapy using specific protein kinase inhibitors is generally considered to be a less 
toxic intervention than traditional pan-cytotoxic chemotherapeutic agents and has been received 
with enthusiasm in the field of cancer therapy research. The effectiveness, for example, of 
Gleevec (Imatinib) in many malignancies serves as a role-model for further targeted therapy 
modalities through tyrosine kinase inhibition. Several clinically feasible strategies exist that can 
block RTK signaling (Fig. 14). The most common approach is via small-molecule compounds 
that compete with ATP for binding in the kinase catalytic domain. Alternatively, monoclonal 
antibodies that specifically bind to the receptor extracellular domain impair RTK signaling by 
various mechanisms, for example by the prevention of ligand binding, receptor endocytosis or 
receptor degradation. Furthermore, monoclonal antibodies, peptides or fusion proteins that bind 
the ligand can be employed to preclude ligand-dependent RTK activation. Although the latter 
approach would be ineffective against RTKs with constitutively active forms, the fact that 
activating TAM mutations have not been described has led to all three strategies being 
investigated and employed as methods of TAM receptor inhibition (203).  
So far, several small-molecule TKIs have been described in the literature that exhibit activity 
against Axl. Due to high identity in the kinase domains of TAM receptors, these inhibitors may 
also show some degree of activity against MerTK and Tyro3. The c-Kit/Axl inhibitor 
Amuvatinib (MP-470, SuperGen) was the first compound reported to have Axl inhibitory 
activity (204). Initially designed as a c-Kit inhibitor, this TKI is more selective for c-Kit and Met 
than for Axl. In gastrointestinal stromal tumors (GIST), Axl and Gas6 are upregulated in 
Imatinib-resistant GIST cells, indicating autocrine activation. More importantly, Amuvatinib in 
synergy with docetaxel is cytotoxic to GIST cells (204). It is also active against PDGFR and the 
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Figure 14. Molecular strategies for therapeutic inhibition of RTKs. 
A. Low molecular weight tyrosine kinase inhibitors (TKIs) compete 
with ATP for binding to the activation loop of the RTK. B-D. Anti-
RTK monoclonal antibodies can prevent binding of ligand (B) and/or 
cause endocytosis of the RTK (C) that may result in RTK 
degradation (D). E. Ligand sequestration via anti-ligand monoclonal 
antibodies or recombinant fusion proteins such as the extracellular 
RTK domain fused to the Fc region of human IgG. (Taken from 
(203)).  
 
DNA repair protein RAD51 and has 
demonstrated a clinical benefit in Phase I 
trials against NSCLC, neuroendocrine 
and endometrial tumors.  
Bosutinib (SKI-606, Wyeth now 
PF5208763, Pfizer) was developed 
initially as a more potent derivative of 
the dual Src/Abl kinase inhibitor than 
Imatinib. In breast cancer cell lines, 
Bosutinib shows a strong inhibitory 
action against Axl and results in a 
decrease in cell motility and invasion 
(205). Bosutinib is currently in Phase II trials for breast cancer and Phase III trials for CML 
(203).  
Foretinib (GSK1363089) is a multi-kinase inhibitor against Axl, MET, and VEGFR and is 
currently in Phase II clinical trials. In Lapatinib-resistant, HER2-positive, ER-positive breast 
cancer cells, overexpression of Axl has been reported as a novel mechanism of acquired 
resistance to HER2-targeted drugs (206). In Lapatinib-resistant cells, inhibition or down-
regulation of Axl restores cell sensitivity to the drug. Additionally, Foretinib acts synergistically 
with Lapatinib to inhibit PKB and ERK phosphorylation and leads to a decrease in cell growth 
and viability (206). Foretinib itself has shown benefit in renal cell carcinoma and hepatocellular 
carcinoma and is being tested in Phase II trials of metastatic gastric cancer and head and neck 
squamous cell carcinoma (203).  
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BMS-777607 (Bristol-Myers Squibb) was initially developed as a Met inhibitor. Interestingly, 
it is more selective for Axl (IC50 = 1.1 nM) than its intended target, Met (IC50 = 3.9 nM). Given 
the high identity of sequence homology in the kinase domain, BMS-777607 also inhibits MerTK 
(IC50 = 16 nM) and Tyro3 (IC50 = 4.3 nM) (207). This agent has proved of benefit in a xenograft 
model of human gastric carcinoma and was studied in a Phase I/II trial for advanced or 
metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck 
squamous cell carcinoma and type I papillary renal cell carcinoma (203).  
R428, a selective small-molecule inhibitor of Axl discovered and synthesized by Rigel, 
exhibits potent activity against Axl (IC50 = 14 nM) (208). The molecule effectively inhibits Axl 
phosphorylation and Axl-dependent breast cancer cell invasion, as well as pro-inflammatory 
cytokine production. It reduced metastatic burden and extended survival in two different mouse 
models of breast cancer and has exhibited favorable pharmacokinetic and toxicity profiles in 
preclinical studies. Additionally, this inhibitor synergizes with cisplatin to suppress liver 
metastasis (208). Selective Axl inhibition by R428 may be a promising strategy for metastatic 
tumor treatment. In addition, aberrant activation of Axl is observed in mesotheliomas. 
Suppression of Axl activity using another Axl inhibitor DP-3975 reduces cell migration and 
proliferation by interfering with the PI3K/PKB/mTOR and RAF/MAPK signaling pathways 
(209).  
Inhibitory monoclonal antibodies blocking Axl have also been reported. An antibody against 
the extracellular domain of Axl decreased motility and invasiveness of breast cancer cell lines 
(199). Another Axl monoclonal antibody, MAb173, was shown to induce receptor degradation 
and inhibit Kaposi sarcoma cell invasion. MAb173 also reduced tumor growth, increased tumor 
cell apoptosis and decreased Axl protein levels in in vivo xenografts with Kaposi sarcoma cells 
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(210). In an NSCLC xenograft mouse model, Axl monoclonal antibodies attenuated tumor cell 
proliferation and induced apoptosis by down-regulation of receptor expression. The authors 
assumed that therapeutic antibodies targeting Axl may block Axl activity not only in malignant 
tumor cells but also in the tumor stroma (199). YW327.6S2, a phage-derived monoclonal 
antibody against both human and mouse Axl, blocks Gas6 binding to the receptor, mitigates 
receptor expression and activation, and also inhibits downstream signaling. In the A549 NSCLC 
model, YW327.6S2 enhanced the effect of erlotinib and chemotherapy, and significantly 
suppressed xenograft tumor growth. It also reduced tumor-associated vascular density and 
potentiated anti-VEGF treatment. Moreover, this antibody attenuated the metastasis of tumor 
cells to distant organs and inhibited the secretion of inflammatory cytokines and chemokines 
from tumor-associated macrophages in an MDA-MB-231 breast cancer model (211). While these 
data may be of value in the identification of novel therapeutic targets, further preclinical testing 
of these antibodies is required before they reach clinical trials.  
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2. Scope of this thesis 
In our laboratory, microarray analysis has been performed on 30 brain tumor samples using 
non-neoplastic brain tissue and normal human astrocytes as controls (212). MerTK was one of 
the identified kinases that were substantially up-regulated in GBM tumors. The results were 
further validated by quantitative RT-PCR analysis on brain tumor samples (Morin P, 
unpublished data).  
Aberrant expression of MerTK has been reported in several human cancer types, including 
breast and prostate cancer, melanoma and leukemia. GBM is the most malignant and lethal brain 
tumor, with only 14 months medium survival after diagnosis. Importantly, how MerTK 
contributes to elevated tumor malignancy in GBM remains to be elucidated. The general aim of 
this thesis was to identify the function of MerTK in GBM. 
In this study, overexpression of MerTK was found in ~90% of GBM tumors. Upregulation of 
MerTK not only protected cells from DNA damage-induced apoptosis, but also significantly 
increased cell invasion in 3D culture. MerTK-promoted tumor cell invasion is strongly 
dependent on its autophosphorylation-induced activity, as illustrated by dramatically suppressed 
pro-invasive and anti-apoptotic potentials upon knockdown of MerTK or expression of an 
unphosphorylable mutant. In conclusion, the data reveal a novel function for MerTK in GBM 
cell survival and invasion, providing a promising target against malignant gliomas.  
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3.    Results and discussion 
 
 
 
 
 
 
 
Mer receptor tyrosine kinase promotes invasion and survival in 
glioblastoma multiforme 
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3.1     Abstract 
The infiltration of glioma cells into adjacent tissue is one of the major obstacles in the therapeutic 
management of malignant brain tumors, in most cases precluding complete surgical resection. 
Consequently, malignant glioma patients almost invariably experience tumor recurrences. Within 
the brain, glioma cells migrate rapidly either amoeboidly or mesenchymally to invade 
surrounding structures, in dependence on the extracellular environment. In addition, radiotherapy, 
frequently applied as adjuvant therapeutic modality, may enhance tumor cell mobility. Here we 
show that the receptor tyrosine kinase Mer (MerTK) is overexpressed in glioblastoma multiforme 
(GBM) and that this is accompanied with increased invasive potential. MerTK expression is 
maintained in primary GBM-derived tumor spheres under stem cell culture conditions but 
diminishes significantly in serum-containing cultures with concomitant down-regulation of Nestin 
and Sox2. Depletion of MerTK disrupts the rounded morphology of glioma cells and decreases 
their invasive capacity. Furthermore, the expression and phosphorylation of myosin light chain 2 
(P-MLC2) are strongly associated with MerTK activity, indicating that the effect of MerTK on 
glioma cell invasion is mediated by actomyosin contractility. Finally, DNA damage robustly 
triggers the upregulation and phosphorylation of MerTK, which protects cells from apoptosis. 
This effect is strongly impaired upon MerTK depletion or overexpression of an inactive MerTK 
mutant. Collectively, our data suggests that MerTK is a novel therapeutic target in the treatment 
of the malignant gliomas. 
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3.2     Introduction  
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, 
characterized by rapid growth, high degree of invasiveness and resistance to standard adjuvant 
treatments. GBMs have been subdivided into “primary” and “secondary” on the basis of 
molecular signatures and clinical characteristics. Secondary GBMs derive from the progressive 
transformation from a preexisting lower grade astrocytic tumors, while primary GBMs have no 
evidence of prior symptoms or antecedent lower grade pathology (1). Although the median 
survival after diagnosis of GBM patients has improved from 10 to 14 months in the last 5 years, 
there is still no effective treatment for this malignant cancer (2). Thus, the demand remains for 
therapies improving survival and maintaining quality of life.  
The infiltrative growth behavior of GBM is a major therapeutic challenge. Clinical treatments 
that include radio/chemotherapy after surgery enrich CD133
+ 
cells and increase tumor 
aggressiveness (3, 4). The neural extracellular matrix (ECM) lacks typical proteins of other 
tissues, such as collagen, fibronectin and type-I laminin, and instead expresses hyaluronic acid 
and associated glycoproteins as well as proteoglycan fibers (5). Migrating glioma cells in vivo 
have a rounded, amoeboid morphology and invade adjacent brain tissue by gliding through the 
limited extracellular space (6). In addition, coordinated cross-bridging between non-muscle 
myosin II and actin is shown to be crucial for glioma cell invasion in vivo (6).  
MerTK, which is named after its predominant expression in monocytes, cells of epithelial, and 
reproductive origin (7), belongs to the Tyro3, Axl and Mer (TAM) receptor tyrosine kinase family. 
The ligands of TAM receptors are protein S and growth arrest specific gene 6 (Gas6) (8). As 
MerTK has a low binding affinity for these ligands, other unknown ligand(s) or conditions may 
be required for MerTK activation (9). Full activation of MerTK requires the autophosphorylation 
of tyrosine 749, 753 and 754 within the kinase domain (10). MerTK knockout mice are fertile and 
viable but gradually develop lupus-like autoimmune disease as well as retinal dystrophy due to 
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reduced efficiency of apoptotic cell clearance (11, 12). Dysregulated MerTK plays important roles 
in tumorigenesis (13). A chimeric receptor with a substitution of the MerTK extracellular domain 
by macrophage colony-stimulating factor receptor (FMS) is able to transform NIH3T3 cells (14). 
MerTK is overexpressed in several cancer types, including mantle cell lymphomas (15), prostate 
cancer (16), breast cancer (17) and melanoma (18). In addition, MerTK knock-in mice with 
ectopic expression in thymocytes and lymphocytes develops T-cell lymphoblastic 
leukemia/lymphoma (19). Recently, MerTK was found to be upregulated in the mesenchymal 
subtype of primary GBMs (20). Nevertheless, the mechanisms of MerTK activation and its 
activity in brain tumor progression remain unclear. 
We have found that MerTK is overexpressed in GBM and GBM-derived spheres compared 
with non-neoplastic brain tissue and normal human astrocytes, and is mitigated upon 
differentiation. MerTK maintains the rounded morphology of GBM cells under stem cell culture 
conditions. Knockdown of MerTK decreases cell infiltrative capacity and increases cell 
sensitivity to Etoposide-induced apoptosis. We further show that MerTK autophosphorylation is 
essential for its anti-apoptotic and pro-invasive activities. Depletion of MerTK attenuates the 
expression and phosphorylation of myosin light chain 2 (MLC2). These results identify novel 
activities of MerTK in glioma cell invasion and survival. 
 
3.3     Materials and methods 
Patients  
Tissue samples of primary GBM were processed as described previously (21) in accordance with 
the guidelines of the Ethical Committee of the University Hospital of Basel and the University 
Hospital of Düsseldorf. Tumors were diagnosed and graded according to the World Health 
Organization (WHO) Classification of Tumors of the Nervous System (22).  
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Construction of plasmids 
The inactive MerTK autophosphorylation mutant MerTKY749FY753FY754F (MerTK-mut) (10) 
was generated by site-directed mutagenesis according to the manufacturer's instructions 
(Stratagene). Short hairpin RNA pairs 5'- 
GATCCCGGATGAACTGTATGAAATATTCAAGAGATATTTCATACAGTTCATCC 
TTTTTGGAAA-3' and 5'- AGCTTTTCCAAAAAGGATGAACTGTATGAAATA 
TCTCTTGAA TATTTCATACAGTTCATCC GG-3' (targeting sequence was underlined) 
targeting human MerTK were inserted into the pSuper.retro.puro vector and pSuper.retro.puro-
shLuc was used as a control (23).  
 
Cell culture and retroviral infection 
Human GBM cell lines BS125, BS149, LN229, LN319 and U373 were cultured in DMEM 
supplemented with 10% FBS [the “BS” series was generated at the University of Basel, while the 
“LN” series was the gift of Erwin Van Meir in Lausanne, Switzerland (24)]. The GBM-derived 
spheres GBM-7S (25), GBM-21S and GBM-22S were obtained from Virginie Clément 
(University Hospitals and University of Geneva). These spheres were maintained in serum-free 
NeuralBasal Medium (NBM) (NBM, Invitrogen) supplemented with B27 (Invitrogen), N2 
(Invitrogen), antibiotics (Invitrogen) and Glutamax (Invitrogen), plus 20 ng/ml EGF and 20 ng/ml 
bFGF from Peprotech. U373 GBM cells transfected
 
with pcDNA3.1(-) (vector), pcDNA3.1(-)-
MerTK (MerTK-wt) or pcDNA3.1(-)-MerTK-mut (MerTK-mut) were selected in the presence of 
1 mg/ml G418 (Gibco).
. To produce recombinant retrovirus, 10 μg of DNA was transfected into 
5x10
6
 packaging cells in a 10-cm dish. After 24 h, the medium was replaced and incubated further 
at 32˚C for 48 h. For GBM-7S sphere infection, the cells were washed with PBS to fully remove 
FBS and refreshed with NBM. To infect targeting cells, the supernatant containing recombinant 
retroviruses was filtered (0.45 μm, Millipore) and incubated with the cells for 24 h in DMEM or 
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NBM at 37˚C. Infected U373 cells and GBM-7S spheres were selected in the presence of 1 μg/ml 
and 4 μg/ml of puromycin, respectively.  
 
Antibodies 
MerCT was raised against the C-terminus of human MerTK (amino acids 856-999). Antisera 
were purified by affinity purification and characterized by western blotting, immunoprecipitation 
and immunohistochemistry (Supplementary Fig. S1A-C). The anti-MerTK mouse monoclonal 
antibodies 15R and 49S were raised against human MerTK (amino acids 536-999) and 
characterized by ELISA, dot-blot and western blotting (Supplementary Fig. S1D). MerTK mouse 
monoclonal antibody CVO-311 was from Caveo Therapeutics, Inc., MerTK rabbit monoclonal 
Y323 from Abcam, and P-MerTK antibody from FabGennix Inc.. P-MLC2 Ser19 and cleaved 
Caspase-3 antibodies were from Cell Signaling, cleaved PARP antibody from BD Transduction 
Laboratories, GFAP and total MLC2 antibodies (MY21) from Sigma, and Nestin and Actin 
antibodies from Santa Cruz. Alexa Fluor 647 phalloidin, goat anti-rabbit Alexa 488, goat anti-
mouse Alexa 568 and goat anti-rabbit Alexa 647 were from Invitrogen and the Sox2 antibody 
from R&D Systems. 
 
Immunofluorescence microscopy 
Cells were processed for immunofluorescence as described previously (26). To avoid 
morphological disruption by centrifugation, GBM spheres were precipitated by gravity. The 
medium was aspirated and the spheres were fixed with 4% PFA for 30 min and then 
permeabilized and blocked in 0.3% Triton X-100, 2% FBS and 1% BSA for 1 h. Incubation with 
primary antibodies was performed overnight at 4˚C, followed by incubation with the secondary 
antibody for 1 h. DNA was counterstained with DAPI in VECTASHIELD mounting medium 
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(Vectorlabs). Photographic images were obtained with a Zeiss Z1 wide-field microscope and 
processed in Photoshop 6.0 (Adobe Systems Inc.). 
 
Immunohistochemistry 
Staining was performed with an automated instrument-reagent system (Discovery XT, Ventana 
Medical Systems Inc.). Hematoxylin-counterstained sections were photographed (Nikon, YTHM) 
and analyzed using ImageAccess Enterprise7 software.  
 
Immunoblotting and immunoprecipitation  
Protein extracts from tissues and cells were homogenized in immunoprecipitation (IP) buffer (20 
mM Tris, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM EDTA, 0.5 mM EGTA, 20 mM 
β-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM benzamidine, 4 µM leupeptin, 0.5 mM 
phenylmethylsulfonyl fluoride [PMSF], 1 µM microcystine, and 1 mM dithiothreitol [DTT] at pH 
8.0) and subjected to western blotting. For IP, the supernatant was incubated with anti-MerTK 
antibody MerCT overnight and incubated subsequently with protein A-Sepharose (GE healthcare) 
for 3 h at 4˚C before the beads were washed four times in IP buffer and analyzed by SDS-PAGE.  
 
Quantitative real-time PCR analysis  
RT-PCR reactions on DNAase-treated RNA were performed using 2X SYBR Green mix 
(Applied Biosystems) and an ABI Prism 7000 sequence detection system (Applied Biosystems). 
Relative expression of MerTK was normalized to the amount of eukaryotic translation elongation 
factor 1 alpha 1 (EEF1A1), a transcript that showed little variation in our microarray data (27). 
MerTK was detected using forward and reverse primers 5’-ACTTCAGCCACCCAAATGTC-3’ 
and 5’- GGGCAATATCCACCATGAAC - 3’.  
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Cell detachment assay 
Dissociated GBM-7S spheres expressing shLuc or shMerTK were seeded in triplicate onto 12-
well plates (0.3 × 10
6 
/ well) and incubated for 2 h. For U373 stable cell lines, cells were 
trypsinized and washed with PBS to fully remove FBS. Cells were then seeded in triplicate onto 
6-well plates (0.8× 10
6 
/ well) in NBM and cultured for 48 h. The adherent and suspended cells 
were sorted and counted with Vi-Cell (Beckman Coulter).  
 
3D cultures 
Growth factor reduced-Matrigel (GFR-Matrigel, BD Biosciences) (100 μl) was pipetted into BD 
Falcon8-well CultureSlides. Single-cell suspensions (~500 cells in 100 μl NBM) were loaded into 
each well. After 24 h, a further 200 μl of NBM was added and replaced every 2 to 3 days.  
 
γ-IR treatments 
Cells were plated at consistent densities 24 h prior to treatment. Following a single-dose γ-IR 
treatment in a TORREX 120D (Astrophysics Research Corp.) instrument at 5 mA/120 kV and 
0.13 Gy/s, cells were left to recover at 37°C for the indicated times before analysis.  
 
Invasion assay 
The invasive capacity of U373 cells expressing empty vector, MerTK-wt, or MerTK-mut and 
U373 cells infected with pSuper-retro carrying control or MerTK shRNA were evaluated by 
Boyden Chamber Assay (BD BioCoat Tumor Invasion Assay System, BD Biosciences) with 
minor modifications. Briefly, 5 × 10
4 
serum-starved cells were seeded into the upper chamber and 
the bottom wells filled with NBM. After a 22-h incubation, cells that had invaded the Matrigel 
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matrix membrane were counterstained with DAPI. The number of invading cells was counted 
under a fluorescent microscope.  
 
Apoptosis measurement 
Cells undergoing apoptosis were harvested, washed with PBS and subdivided into two fractions. 
One fraction was stained with JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’- 
tetraethylbenzimidazolylcarbocyanine iodide, Molecular Probes) and subjected to flow cytometry 
for detection of mitochondrial depolarization (ΔΨm). Red fluorescence (FL-2 channel) of JC-1 (J-
aggregates) indicated intact mitochondria, whereas green fluorescence (FL-1 channel) showed 
monomeric JC-1 produced by the breakdown of ΔΨm during apoptosis. The remaining cells were 
lysed for western blotting. 
 
3.4     Results 
MerTK is overexpressed in malignant gliomas 
In previous study, we analyzed 30 glioma samples by microarray analysis (27). Consequent 
bioinformatics analysis identified MerTK as one of the candidate genes significantly upregulated 
in GBMs compared with non-neoplastic brain tissue and normal human astrocytes (data not 
shown). Elevated expression of MerTK in GBM samples was further validated by quantitative 
RT-PCR and western blotting (Fig. 1A and B). The variation in molecular weight observed was 
due to differential glycosylation on the extracellular domain of MerTK, as confirmed by treatment 
of whole U937 cell lysates with the deglycosylation enzyme PNGase F, which significantly 
decreased the molecular weight of MerTK (Supplementary Fig. S2) (7, 28). To further analyze 
MerTK expression histologically, we generated MerTK antibodies and confirmed its specificity 
through western blot, immunoprecipitation and immunohistochemistry (Supplementary Fig. S1). 
Immunohistochemical staining of human GBM samples showed that MerTK localized  
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Figure 1. MerTK is overexpressed in malignant gliomas. A, The endogenous MerTK mRNA level was normalized to 
EEF1A1 expression on total RNA isolated from 10 GBM samples, one sample of non-neoplastic brain tissue (NB) and 
normal human astrocytes (NHA). B, Western blotting of MerTK expression in human GBM and non-neoplastic brain 
tissue (NB). C, Immunohistochemical analysis of MerTK expression in GBM samples. TU: tumor mass; IN: infiltrating 
zone. D, Immunofluorescent staining of MerTK and GFAP in primary GBM samples. E, Pathological scoring of MerTK 
expression in 30 primary GBM samples: “0” no, “1” low, “2” medium, “3” high.  
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Figure 2. MerTK is highly expressed in GBM-derived spheres. A, Western blotting of MerTK, Nestin and Sox2 expression in 
immortalized GBM cell lines and GBM-derived spheres. B, Immunofluorescent staining of MerTK expression in three GBM-
derived spheres. Nuclei were counterstained by DAPI. Scale bar 50 μm. C, Morphology of three GBM-derived spheres 
cultured in NBM or DMEM+10% FBS for 10 days. Scale bar 50 μm. D, Western blotting of MerTK, Nestin and Sox2 
expression in three GBM-derived spheres cultured in NBM or in DMEM+10% FBS for 10 days.  
 
predominantly to the cell membrane (Fig. 1C, upper images) and was expressed by cells within 
the solid tumor mass as well as in the infiltration zone (Fig. 1C, lower left), but not in endothelial 
cells (Fig. 1C, lower right). Fluorescence co-immunostaining demonstrated that MerTK was 
expressed by GFAP+ cells of the astrocytic lineage (Fig. 1D). MerTK expression was further 
scored in 30 primary GBM samples and found to be overexpressed in 90% of tumors (27/30) (Fig. 
1E, in collaboration with Stephan Frank, Basel University Hospital).  
 
MerTK is highly expressed in GBM-derived spheres 
Due to the failure of established GBM cell lines to accurately model the human disease, long-term 
expansion of neurospheres from primary GBMs in serum-free medium was used to more 
precisely reflect tumor phenotypes (29). We analyzed the expression levels of MerTK and neural 
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stem cell markers Sox2 and Nestin in immortalized GBM cell lines cultured in serum-containing 
medium and in GBM spheres growing in NBM. Remarkably, in contrast to GBM cell lines, 
MerTK was highly expressed in all three GBM sphere cultures (Fig. 2A), distributed specifically 
to the cell membrane (Fig. 2B). Compared with other GBM cell lines, U373 cells had a relatively 
high level of endogenous MerTK (Supplementary Fig. S3), Sox2 and Nestin (Fig. 2A). GBM 
spheres GBM-7S, GBM-21S and GBM-22S growing under differentiation culture conditions 
showed stellate cell morphology (Fig. 2C) and loss of Nestin, Sox2 and MerTK expression (Fig. 
2D). This discrepancy between MerTK expression in GBM spheres and immortalized GBM cell 
lines implies that MerTK is expressed under conditions that more precisely mimic the in vivo 
tumor microenvironment. 
 
Knockdown of MerTK disrupts the morphology of GBM spheres 
Unlike GBM-21S and GBM-22S, GBM-7S spheres showed both adherent and suspended 
phenotypes during maintenance (Fig. 3A). The differences between adherent and suspended 
spheres have been studied both in vitro and in vivo (30). To examine MerTK expression in this 
situation, we sorted suspended spheres into fresh cultures. As shown in Figure 3A, whilst 
attachment to the substrates did not affect expression of Nestin and Sox2, MerTK was 
significantly downregulated. Depletion of MerTK led to cell attachment (Fig. 3B and C), 
impaired the spherical form of GBM-7S spheres in NBM as revealed by F-Actin staining (Fig. 
3D), and increased branchy cell cluster formation in Matrigel in the presence of NBM (Fig. 3E). 
In fact, over 90% of cell clusters showed a spiky phenotype upon depletion of MerTK (Fig. 3F). 
This suggests that MerTK is involved in regulation of cytoskeletal dynamics.  
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Figure 3. Knockdown of MerTK disrupts the spherical morphology of GBM spheres. A, GBM-7S spheres maintained 
in NBM show both adherent and suspended phenotypes. Sorted adherent and suspended GBM-7S spheres were 
cultured in NBM for 1 week and cell lysates subjected to western blotting for Sox2, Nestin and MerTK. Scale bar 50 
μm. B, Phase contrast images of GBM-7S spheres expressing shLuc or shMerTK. Western blotting showed MerTK 
knockdown efficiency in GBM-7S spheres. Scale bar 50 μm. C, Detachment assay of GBM-7S spheres expressing 
shLuc or shMerTK. Data are shown as the ratio of suspended and adherent cells after being dissociated and seeded in 
NBM for 2 h. Data are representative of experiments in triplicate and are shown as means ± s.d. D, GBM-7S spheres 
expressing shLuc or shMerTK were stained for MerTK and F-Actin. Nuclei were counterstained by DAPI. Scale bar 
20 μm. E, GBM-7S spheres expressing shLuc or shMerTK were cultured in Matrigel in the presence of NBM. Scale 
bar 50 μm. F, Morphology quantification of GBM-7S spheres expressing shLuc or shMerTK cultured in Matrigel in 
the presence of NBM. Results are shown as means ± s.d. of 100 spheres from three independent experiments.  
 
 
Active MerTK maintains rounded cell morphology and invasive capacity 
U373 cells were grown under stem cell culture conditions as reported previously (31). In these 
conditions, cells adopted a round morphology and formed spheres after several days, in parallel to 
increased MerTK expression (Fig. 4A). Interestingly, other GBM cell lines growing under stem 
cell culture conditions either died (data not shown) or showed adherent features with an elongated 
morphology (Supplementary Fig. S4A).  
In order to gain insights into the biological significance of MerTK upregulation, we depleted 
endogenous MerTK in U373 cells by RNA interference. Knockdown of MerTK not only induced 
a distinct morphological change from rounded to elongated and subsequently in a more compact 
and organized sphere formation in NBM (Fig. 4B), but also increased cell attachment 
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Figure 4. MerTK maintains rounded cell morphology and invasive potential. A, U373 cells were grown in serum-containing 
DMEM or NBM for 4 days. Cell morphology was captured and cells were harvested and lysed at indicated time points for 
analysis of MerTK expression by western blotting. Scale bar 50 μm. B, MerTK was knocked down in U373 cells by shRNA 
(two different clones are shown as #1 and #2). U373shLuc and U373shMerTK#1 and #2 cells were cultured in NBM and 
cell morphology photographed after 1 day and 4 days. Knockdown efficiency of MerTK was validated by western blotting. 
Scale bar 50 μm. C, Detachment assay of U373shLuc, U373shMerTK#1 and #2 cells. Data are shown as the ratio of 
suspended and adherent cells after being dissociated and cultured in NBM for 48 h. Data are representative of experiments 
in triplicate and are shown as means ± s.d. D, U373shLuc and U373shMerTK#1 and #2 cells were cultured in NBM for 3 
days and stained for F-Actin. Nuclei were counterstained by DAPI. E, Quantification of rounded cells stained by F-Actin. 
Results are means ±s.d. of 150 cells from three independent experiments. F, Analysis of the invasive potential of 
U373shLuc and U373shMerTK cells. Cells were seeded in Boyden chambers for 22 h and the cells invading the membrane 
revealed by DAPI staining and counted under the microscope. Data are representative of experiments in triplicate and are 
shown as means ± s.d. 
 
(Fig. 4C). Cells expressing shMerTK had a spindle mesenchymal morphology, whilst cells 
expressing shLuc were rounded and amoeboid in shape in Matrigel in the presence of NBM 
(Supplementary Fig. S4B). Interestingly, cells lacking MerTK exhibited multiple membrane 
protrusions, whereas cells expressing shLuc displayed marked cortical F-Actin staining and 
extensive membrane blebbings (Fig. 4D); ~80% of cells lost their rounded morphology upon 
MerTK depletion (Fig. 4E). To test whether knockdown of MerTK impairs cell infiltrative 
potential, we measured the invasive capacity of U373 cells in the presence and absence of MerTK 
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Figure 5. Autophosphorylation of MerTK is required for maintenance of rounded morphology and cell invasive capacity. 
A, U373 cells stably expressing empty vector, MerTK-wt, or MerTK-mut were cultured in NBM and cell morphology 
photographed after 1 and 4 days. P-MerTK and total MerTK were assayed by western blotting. Scale bar 50 μm. B, 
Detachment assay of U373 cells expressing empty vector, MerTK-wt or MerTK-mut. Data are shown as the ratio of 
suspended and adherent cells after being dissociated and cultured in NBM for 48 h. Data are representative of experiments 
in triplicate and are shown as means ± s.d. C, Immunofluorescent staining of F-Actin and MerTK in U373 cells expressing 
empty vector, MerTK-wt or MerTK-mut and cultured in NBM for 24 h. Nuclei were counterstained by DAPI. D, 
Quantification of rounded cells revealed by F-Actin staining. Results are means ± s.d. of 150 cells from three independent 
experiments (** P=0.004). E, The invasive potential of U373 cells expressing empty vector, MerTK-wt or MerTK-mut was 
analyzed by Boyden chamber assay. The cells were seeded in the upper chamber for 22 h and invading cells stained with 
DAPI and counted under the microscope. Data are representative of experiments in triplicate and are shown as means ± s.d. 
The differences between empty vector- and MerTK-wt-expressing cells are statistically significant (* P=0.018). 
 
expression. As shown in Figure 4F, MerTK depletion strongly suppressed U373 cell invasion 
through the Matrigel.  
In order to investigate further whether MerTK activity helps maintain rounded morphology, 
U373 cells stably expressing empty vector, MerTK-wt or MerTK-mut were cultured in NBM. 
Strikingly, wild-type MerTK was rapidly phosphorylated and cells displayed a spherical 
morphology after 4 days in NBM. In contrast, cells expressing MerTK-mut were elongated and 
showed higher adherence, similar to MerTK-depleted U373 cells (Fig. 5A and B). In fact, 
MerTK-mut expression was associated with changes in cellular cytoskeletal organization and 
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Figure 6. MerTK promotes GBM cell invasion by regulating actomyosin contractility. A, Western blotting of total 
MerTK, total MLC2 and P-MLC2 Ser19 in U373 and GBM-7S stable cell lines. U373shLuc, U373shMerTK#1 and #2 
cells were cultured in NBM for 3 days. U373 cells stably expressing empty vector, MerTK-wt or MerTK-mut were 
cultured in NBM for 24 h. B, Immunofluorescent staining of P-MLC2 Ser19 in U373shLuc, U373shMerTK#1 and #2 
cells cultured in NBM for 3 days. Nuclei were counterstained by DAPI. C, Immunofluorescent staining of P-MLC2 Ser19 
and MerTK in U373 cells expressing empty vector, MerTK-wt or MerTK-mut cultured in NBM for 24 h. Nuclei were 
counterstained by DAPI. D, F-Actin staining of U373 cells expressing empty vector or MerTK-wt seeded in NBM and 
treated with 10 μM Blebbistatin (Sigma) for 90 min. E, Quantification of rounded cells stained by F-Actin. Results are 
means ± s.d. of 150 cells from three independent experiments. 
 
resulted in compact sphere structures (Fig. 5C). However, when MerTK-wt was expressed and 
phosphorylated, more cells became rounded in shape with extensive blebbings and showed 
cortical F-Actin localization (Fig. 5C and D). In contrast to cells expressing empty vector or 
MerTK-mut, MerTK-wt-expressing U373 cells possessed an enhanced invasive potential, 
implying an important role for MerTK phosphorylation in cell infiltration (Fig. 5E).  
 
MerTK promotes GBM cell invasion by regulating actomyosin contractility 
Glioma cells migrate as mesenchymal cells in 2D but invade as neural progenitor cells in an 
amoeboid mode in vivo (6). Without degrading ECM, changes in glioma cell shape allow passage 
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of cells through gaps in the tissue environment driven by cortical actomyosin contractility (6). 
Although several proteins, including kinases, have been shown to be involved in cross-bridging 
between actin and myosin, phosphorylation at serine 19 of MLC2 is a prerequisite for actomyosin 
ATPase activity (32). Morphological differences in 3D culture are commonly used to distinguish 
mesenchymally or amoeboidly migrating cells. Since MerTK-depleted cells displayed an 
elongated mesenchymal phenotype, we analyzed MLC2 expression and phosphorylation in U373 
cells and GBM-7S spheres. Knockdown of MerTK or overexpression of MerTK-mut significantly 
decreased MLC2 expression and phosphorylation (Fig. 6A-C). Treating U373 stable cell lines 
with Blebbistatin, a cell-permeable molecule that specifically inhibits myosin II heavy chain 
ATPase activity (33), significantly disrupted rounded cell morphology. This was delayed upon 
expression of wild-type MerTK (Fig. 6D, Supplementary Fig. 5), which suggests that myosin II 
activity-controlled cell motility is dependent on active MerTK. 
 
MerTK is induced upon DNA damage and promotes cell survival 
It has been shown that inhibition of MerTK and Axl in astrocytoma cells increased 
chemosensitivity under differentiation culture condition (34). In this present study, we observed 
that Etoposide treatment substantially induced MerTK expression in adherent GBM-7S cells and 
led to cell detachment (Fig. 7A). Knockdown of MerTK sensitized GBM-7S cells to Etoposide-
induced apoptosis (Fig. 7B). Elevated MerTK expression was detected in U373 cells after DNA 
damage treatment (Fig. 7C). To further dissect the activity of MerTK in GBM, U373 cells stably 
expressing empty vector, MerTK-wt or MerTK-mut were treated with γ-irradiation or Etoposide. 
Interestingly, MerTK phosphorylation was significantly increased, and protected cells from 
apoptosis, as shown by diminished cleaved-PARP and cleaved-Caspase 3 levels (Fig. 7D, 
Supplementary Fig. S6). 
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Figure 7. MerTK is induced upon DNA damage and promotes cell survival. A, Adherent GBM-7S cells were treated with 
50 μM Etoposide (Etop, Sigma) for 48 h and expression of MerTK analyzed by western blotting. Scale bar 50 μm. B, 
Western blotting for cleaved PARP and cleaved Caspase-3 in MerTK-knockdown or shLuc-expressing GBM-7S spheres 
treated with Etoposide at different doses for 40 h. DMSO was used as control. C, U373 cells were γ-irradiated with 10 Gy or 
treated with 5 μM Etoposide and cells lysed at the indicated time points. MerTK expression was analyzed by western 
blotting. D, U373 cells expressing empty vector, MerTK-wt or MerTK-mut were treated with DMSO or 50 μM Etop for 20 
h. Half of the cells were lysed and analyzed by western blotting with the antibodies against total MerTK, P-MerTK, cleaved 
PARP, and cleaved Caspase-3. E, The second half of the cells from (D) were analyzed by flow cytometry for depolarization 
of mitochondrial membrane potential using JC-1: M1 apoptotic cells, M2 viable cells.  
 
An early event initiating DNA damage-induced apoptosis is loss of mitochondrial membrane 
potential, ΔΨm (35). Assessing the apoptotic fraction of cells by measuring ΔΨm after Etoposide 
treatment, we recorded increases in this fraction from 9.3% to 63.7% and from 7.6% to 58.9% in 
empty vector- and MerTK-mut-expressing U373 cells, respectively, but only a 10% increase in 
MerTK-wt-expressing cells (Fig. 7E), demonstrating that MerTK kinase activity is crucial for its 
anti-apoptotic function.  
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3.5     Discussion 
Current standard GBM therapy is restricted to tumor resection and subsequent 
radio/chemotherapy. In the clinic, the majority of patients with primary GBM experience disease 
recurrence within a few months due to the high infiltrative capacity of residual GBM cells (2). 
Although the mechanism is still elusive, radio-resistance and enhanced invasive potential of 
glioma cells after radiotherapy have been reported (4, 36, 37). Upregulation and phosphorylation 
of MerTK upon DNA damage implicates MerTK activity in glioma cell survival and invasion 
after ionizing radiation therapy.  
GBM-derived spheres show highly heterogeneous features as primary tumors including 
extensive infiltration in vivo and resistance to traditional therapies (4, 29). In vitro analyses of 
spheres maintained in suspension, as well as adherent and semi-adherent spheres showed no 
differences in proliferation rate (30). However, the latter displayed either reduced tumor size or a 
well-delineated tumor border in vivo, whilst the suspended spheres always formed infiltrative 
tumors (30). Interestingly, we found that MerTK is strongly suppressed in adherent/semi-adherent 
GBM-7S cells (Fig. 3A). Knockdown of MerTK significantly interfered with cell invasion (Fig. 
4F) without affecting cell proliferation (data not shown). Invasion is initiated when tumor cells 
become detached from the growing tumor mass and enter into the surrounding parenchyma (38). 
Cells lacking MerTK or MerTK activity showed elevated adherent capacity (Figs. 3C, 4C and 5B), 
possibly reflecting the involvement of MerTK activity in the establishment of signaling networks 
between tumor cells and the microenvironment in vivo and, thus, in an early step of tumor cell 
dissemination (39-41).  
Interestingly, MerTK expression and phosphorylation in U373 cells is substantially 
upregulated during culture in NBM (Figs. 4A and 5A). Inactivation of MerTK by mutation of all 
three autophosphorylation sites hampered MerTK pro-invasive and anti-apoptotic activities (Figs. 
5E and 7E), indicating that its kinase activity is crucial for MerTK involvement. Notably, 
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overexpression of inactive MerTK in U373 cells severely decreased cell infiltration capacity (Fig. 
5E), possibly due to its competitive binding to signaling transducer(s), thus negatively influencing 
cell invasion. 
Amoeboid mesenchymal and mesenchymal amoeboid transitions (AMT/MAT) are not rigid 
processes and the actual transition of tumor cells is strongly influenced by the extracellular 
environment (42). Conversion between two different migration patterns is commonly observed in 
cancer cells, including glioma cells (6, 42). The force leading to penetration of amoeboidly 
migrating cells through the extracellular matrix is sustained by cortical actomyosin contractility, 
which results in plasma membrane blebbing (43). As we found that MerTK was required for the 
maintenance of rounded cell morphology and invasive capacity, it was hypothesized that MerTK 
positively regulates blebbing-associated MAT. Amoeboid migration depends largely on myosin 
activity regulated by the RhoA-ROCK signaling pathway via activation of MLC2 (44). Our data 
demonstrate that knockdown of MerTK significantly attenuates the level of total MLC2 and P-
MLC2 Ser19 (Fig. 6A-C). Unlike U373 cells with a rounded amoeboid morphology under stem 
cell culture conditions, BS125, BS149 and U87MG cells survived but displayed elongated 
mesenchymal patterns (Supplementary Fig. S4A). We did not detect upregulation of MerTK in 
such cells cultured in NBM (data not shown), suggesting that such GBM cell lines may not be 
amoeboidly mobile. MerTK was reported to regulate myosin II distribution during retinal pigment 
epithelial phagocytosis through association with the heavy chain of myosin IIA (40). U373 cells 
expressing MerTK not only showed increased P-MLC2 Ser19 but were also more resistant to 
Blebbistatin treatment (Fig. 6A and D, Supplementary Fig. S5). These data suggest that MerTK 
may promote cell invasion by the regulation of myosin II activity.  
Mesenchymally migrating cancer cells secret MMPs, which facilitates metastasis or invasion 
(45). Although invasive glioma cells migrate in vitro by degrading the pericellular matrix, in vivo 
studies suggest that Matrix Metalloproteinase (MMP)-dependent proteolysis in gliomas does not 
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play a significant role (6). Clinical trials of MMP inhibitors did not reveal evident benefits in the 
case of GBM or other cancer types (46). Previous studies have demonstrated that cancer cells are 
able to invade in 3D after treatment with an MMP inhibitor cocktail, whilst showing the typical 
features of amoeboid invasiveness during migration; this indicates that blocking ECM proteolysis 
promotes MAT (42, 47). Inhibition of the ATPase activity of actin and myosin could reduce cell 
motility (48), but targeting such fundamental cytoskeleton components might have severe side-
effects. A further attractive therapeutic strategy for GBM treatment has been to target cell surface 
growth factor receptors such as EGFR, PDGFR and VEGFR. However, due probably to the 
unique biology of each glioblastoma and the redundant nature of signaling pathways, the overall 
clinical outcome has proven unsatisfactory (2). As a receptor tyrosine kinase, MerTK is not 
expressed in normal brain. DNA damage-induced/activated MerTK may not only promote GBM 
cell survival, but may also engage in tumor cell invasion. Thus, combinatory targeting MerTK 
together with other “switches” of signaling pathways may be of future therapeutic value in GBM 
treatment.  
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3.6     Supplementary data  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S1. Characterization of MerTK antibodies. A, Raw serum from an immunized rabbit was diluted 1:5000 
in 5% non-fat milk in TBS and characterized by western blotting. Protein (50 μg) was loaded from whole cell lysates of U937 
cells and BS125 GBM cells transfected with empty vector or MerTK-wt. B, Raw serum was purified by affinity purification 
and used to immunoprecipitate endogenous MerTK from U937 cells. Immunoprecipitation efficiency was analyzed by 
western blotting using the MerTK monoclonal antibody CVO-311. C, U373 cells expressing empty vector or MerTK-wt were 
spun down by Cytospin and immunohistochemistry was performed using MerCT at 1:100 dilution. Staining was carried out 
using an automated instrument-reagent system (Discovery XT, Ventana Medical Systems Inc.). Scale bar 50 μm. D, Whole 
cell extracts from U373 and K562 transfected with shRNA against MerTK or luciferase and from U937 cells were used to 
examine the specificity of MerTK monoclonal antibodies 15R and 49S by western blotting. 
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Supplemental Figure S2. Deglycosylation of MerTK in U937 cells. U937 human monocytic cell 
lysates were deglycosylated with PNGase F (NEB) according to the user manual. MerTK expression 
was analyzed by western blotting. 
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Supplemental Figure S3. Western blotting using MerTK polyclonal antibody MerCT on whole cell extracts of 
immortalized GBM cell lines. 
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Supplemental Figure S4. A, BS125, BS149 and U87MG GBM cell lines were cultured in NBM for 5 days and cell 
morphologies photographed. Scale bar 50 μm. B, Morphology of U373shLuc, U373shMerTK#1 and #2 cells 
cultured in Matrigel in the presence of NBM. Images were captured after 1 and 8 days. Scale bar 50 μm. 
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Supplemental Figure S5. Phase contrast images of U373 cells expressing empty vector or MerTK-wt growing 
in NBM treated with 10 μM Blebbistatin or DMSO for 16 h. Scale bar 25 μm. 
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Supplemental Figure S6. U373 cells stably expressing empty vector, MerTK-wt and MerTK-mut were γ 
irradiated with 10 Gy and cells lysed at the indicated time points. Total MerTK and P-MerTK were 
analyzed by western blotting. 
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4.   General discussion 
Radiotherapy is the most effective therapeutic modality for glioblastomas, significantly 
contributing to the prolongation of patient life expectancy. However, although many 
glioblastomas respond initially, they invariably all recur, even in combination with surgery and 
chemotherapy. The mechanisms underlying tumor radioresistance have remained poorly 
understood and in recent years intensive studies have been conducted to investigate the 
determinants of radiosensitivity and to evaluate radiosensitizers. Recent evidence suggests that a 
small population of clonogenic cells, known as tumor stem-like cells (TSC), contributes to 
glioma radioresistance through preferential activation of the DNA damage checkpoint response 
and an increase in DNA repair capacity (7). Stratification of glioma cells with or without a stem-
like character has been based on the expression of the stem cell-associated protein CD133. The 
fraction of CD133-expressing cells was shown to be enriched and to survive radiotherapy, 
suggesting that this cellular population may potentially confer glioma radioresistance and could 
be the source of tumor recurrence and invasion after radiation. 
The vast catalog of cancer cell genotypes has been proposed to be a manifestation of six 
primary cellular functions that normal cells acquire during oncogenesis: self-sufficiency in 
growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (213). As in most cancers, 
the major pathways contributing to these changes are related to inactivation of key molecules, 
such as PTEN, p53, p16
INK4a 
or p14
ARF
 or to upregulated EGFR or PDGFR autocrine/paracrine 
signaling cascades in GBM (214, 215). However, the first generation of molecular agents 
targeting tumor growth pathways in GBM have been disappointing. One explanation for the 
failure of targeted molecular agent monotherapy comes from the coactivation of multiple 
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receptor tyrosine kinases in GBM cell lines and primary cultures. Another major hindrance to the 
use of chemotherapy agents for GBM is that the brain is well protected behind the BBB, which 
effectively excludes targeted molecular drugs from the central nervous system (216). Thereby, 
successful strategies against GBM will have to include the induction of GBM cell destruction, 
and not merely anti-proliferative or anti-angiogenic effects, since invasive tumor cells infiltrate 
normal brain tissue independently of neo-vascularization. Meanwhile, systemically administered 
drugs must be able to penetrate the BBB and to target invasive GBM cells beyond the areas of 
the visible main tumor mass. 
In this study, MerTK was found to be overexpressed in GBM tumors but is negative in 
normal brain tissues, suggesting that inhibition of MerTK may have maximal effects on the 
disease state but with minimal toxicity. Interestingly, expression of MerTK is upregulated upon 
DNA damage and this promotes tumor cell survival and invasion. The pro-invasive potential of 
MerTK has also been reported in breast cancer. Lung metastatic MDA-MB-231 (LM2) cells 
exceptionally express MerTK and this is inversely regulated by miR-335. Depletion of miR-335 
in LM2 cells substantially increases expression of MerTK and to some extent other genes 
involved in tumor progression, such as Tenascin C, which suggests strongly that MerTK is an 
active factor in breast cancer invasion/metastasis (96). However, an improved understanding of 
MerTK signaling is a prerequisite for the efficient development as well as implementation of a 
targeting strategy. As MerTK is a receptor tyrosine kinase, small-molecule tyrosine kinase 
inhibitors or monoclonal antibody blockage of ligand-binding induced activation may improve 
the efficacy of current treatments for malignant gliomas and for other cancers.  
In recent decades, immortalized cancer cell lines have been widely used as models to explore 
the biology of human cancers and to screen for potential therapeutic agents. However, it becomes 
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increasingly clear that cancer cell lines repeatedly passaged in vitro often reflect inadequately the 
phenotype of the corresponding primary human tumors (217). In contrast, brain tumor stem cells 
isolated from glioblastoma specimens harbor characteristics of continuous self-renewal, 
extensive brain parenchymal migration/infiltration, and the potential for full or partial 
differentiation properties not found in conventional glioma cell lines cultured in serum-rich 
medium. In addition, brain tumor stem cells also express neural stem cell markers and are able to 
grow as nonadherent spheres when maintained in the presence of EGF and bFGF under serum-
free conditions. In contrast to primary GBM samples and GBM-derived spheres, MerTK 
expression is extremely low in immortalized GBM cell lines. Interestingly, the expression of 
MerTK is substantially upregulated in U373 cells grown under stem cell culture conditions. 
Depletion of MerTK in U373 cells and GBM-derived spheres not only disrupts cell morphology 
but also impairs tumor cell invasion. This discrepancy between MerTK expression in GBM 
tumors and cell lines suggests that expression of MerTK requires conditions that reflect more the 
tumor microenvironment. It would be very exciting to design in vivo experiments to test whether 
inactivation of MerTK in GBM cells can attenuate gliomagenesis or synergize with 
chemotherapy or radiotherapy. It would also be interesting to verify whether overexpression of 
MerTK in glia cells is tumorigenic per se and/or cooperates with established tumor pathways in 
the development of glioblastomas. This type of data could be of value in understanding MerTK 
signaling in GBM, as well as its possible contribution to therapy resistance and recurrent cancers 
in vivo. In the long term, such findings could be useful for designing future therapies.  
Aberrant expression/activation of TAM receptors, especially Axl, has been studied in many 
cancers. Axl was shown to promote cancer cell proliferation, survival and invasion in different 
contexts (66). In glioblastoma, overexpression of Axl and Gas6 predicts poor prognosis for GBM 
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patients (103). Although Gas6 is generally seen as the ligand of TAM members, MerTK has the 
lowest affinity, suggesting that further factors or conditions are involved in MerTK activation in 
GBM. Recently, Tubby and Tulp1 have been identified as new MerTK ligands for phagocytosis, 
further supporting this hypothesis (218). In the future, it will be very important to work out the 
mechanism of MerTK activation in GBM, and another question that arises immediately is that of 
the downstream signaling targets of MerTK. Previous studies have shown that tyrosine 872 of 
MerTK can bind to Grb2, recruit PI3K subunit p85 and transcriptionally activate NF-κB (183). 
MerTK is also reported to interact with VAV1 and govern the ingestion of apoptotic cells by 
precisely coordinating cytoskeleton changes in macrophages (178). To dissect MerTK signaling 
pathways, in this present study MerTK-expressing U373 GBM cells were treated with the 
PI3K/mTOR dual inhibitor NVP-BEZ235 and/or the MEK1/2 inhibitor U0126. Surprisingly, 
either individually or in combination, the two inhibitors did not interfere with MerTK anti-
apoptotic activity (Yuhua Wang, unpublished data), further demonstrating that, in addition to the 
key cellular pathways around PI3K/PTEN/PKB, RAS/RAF/ERK and mTOR/S6K/S6, the 
targeting of other accessory and complementary genes and pathways that are aberrantly 
expressed, such as MerTK signaling, may represent excellent therapeutic interventions.  
Surgical removal of the GBM tumor mass temporarily improves the patient’s condition, but 
the capacity of GBM cells to infiltrate adjacent brain tissue and extend beyond the visible 
borders of the tumor invariably leads to tumor recurrence (219). The migration of tumor cells is a 
prerequisite for tumor cell invasion and metastasis development. Although inhibiting migration 
of GBM cells alone will not be sufficient to control tumor development, understanding the key 
molecular mechanisms necessary for cell invasion should help in the design of highly potent 
drug combinations with anti-migratory as well as pro-apoptotic properties. The unique 
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composition and properties of the neural parenchyma are believed to be refractory to cell motility 
and axonal extension. However, distinct mechanisms may be present in glioma cells that 
promote their interaction with a variety of substrates with different topography and molecular 
composition. This would, unfortunately, potentiate reactions to a changing microenvironment 
through matrix remodeling, cytoskeletal reorganization, and phenotype transition from highly 
proliferative to migratory. Although GBM cells secrete MMPs, which facilitates migration, 
MMP inhibition brought no survival benefit in glioblastoma patients (220, 221). Interestingly, 
glioma cells in the living brain migrate like nontransformed, neural progenitor cells that require 
myosin II activity. In contrast, on a 2D surface, glioma cells move more like fibroblasts 
independent of myosin II activity (15). PDK1 has been shown to maintain the rounded 
morphology and affect cancer cell motility by antagonizing inhibition of ROCK1 by RhoE (222). 
In this study, PDK1-mediated cortical actomyosin contractility is particularly important for cell 
migration in the 3D environment, but often not prominent on rigid 2D substrates. Consistent with 
the observation in this study that MerTK is not induced in all GBM cells lines under stem cell 
culture conditions, tumor cell lines that do not exhibit rounded or amoeboid motility did not 
require PDK1 for invasion (222). While PDK1 kinase activity is not essential for rounded cell 
morphology, phosphorylation of MerTK was found to be important for amoeboid invasion. 
There was no evidence to show that MerTK is relevant to PDK1-dependent cytoskeleton 
regulation, but instead the present study further demonstrated the complex and redundant 
signaling networks of cytoskeleton modulation and tumor cell invasion mechanisms. Notably, 
overexpression of an unphosphorable MerTK mutant severely reduced cell infiltration capacity, 
possibly due to its competitive binding to signaling transducer(s), thus negatively influencing 
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cell invasion. To dissect the function of the active and inactive MerTK complex opens up novel 
and interesting research directions.  
In the physiological context, interaction between MerTK and myosin IIA is needed for retinal 
pigment epithelial phagocytosis in parallel with myosin IIB activation (144). However, 
oncogenic activity of MerTK-mediated myosin II activation has not been reported. Nonmuscle 
myosin II is a ubiquitous molecular motor comprising three isoforms (A, B and C). All 
vertebrates examined to date express at least two isoforms, myosin IIA and myosin IIB. The 
Myosin II isoforms regulate cell polarity, adhesion and migration in a variety of cell types 
through binding to and contracting filamentous actin (F-actin) in an ATP-dependent manner.  
A number of studies in mammalian cells have revealed that the three myosin IIs are regulated 
in a similar fashion, i.e., through the phosphorylation of MLC2 (223). Phosphorylation at Ser-19 
of MLC2 both elevated the actin-activated ATPase activity of myosin II and promoted myosin II 
filament assembly. Isoform-specific RNA interference showed that depletion of myosin IIA 
produces a cell phenotype similar to that following ROCK inhibition. This suggests that myosin 
IIA is specifically required for contractile events downstream of the Rho-ROCK signaling 
pathway (224, 225). 
In agreement with the observation in the present study that overexpression of MerTK shows 
little effect on U373 cell motility under differentiation culture conditions (Yuhua Wang, 
unpublished data), myosin IIA-depleted cells were reported to have impaired thrombin-induced 
cell rounding and to assume a more motile phenotype (224). Additionally, thrombin 
preferentially induced phosphorylation of myosin IIA-MLC2 through the Rho-ROCK signaling 
cascade, whilst the phosphorylation status of myosin IIB-MLC2 was not affected (224). 
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Figure 15. Model of MerTK induction and activation and functions in 
glioma cells. The standard therapeutic modalities are able to induce cell 
cycle arrest and kill tumor cells. However, under those extreme 
conditions, a number of proteins, including MerTK, are specifically 
induced and activated in certain population of cells, precluding cells from 
apoptosis and promoting invasion. 
Mesenchymally migrating cells 
display an elongated cell shape and 
require extracellular proteolysis and 
integrin engagement, depending on 
Rac1-mediated cell polarization and 
lamellipodia formation. Conversely, 
amoeboidly moving cells have a 
rounded morphology, independent of protease activity, but require high Rho GTPase activity to 
drive elevated levels of actomyosin contractility (226). In human monocytes, ligand-dependent 
MerTK activation results in tyrosine phosphorylation and the release of Vav1 from MerTK, and
subsequently activates Rac1, Cdc42, and RhoA (178). Since Vav1 is specifically expressed in the 
hematopoietic system, MerTK likely regulates RhoA activity by binding to adaptor proteins such 
as Grb2 and recruiting other GEFs (183, 227). In this present study, overexpression of MerTK 
not only delayed a cell response to Blebbistatin treatment, but also upregulated MLC2 expression 
and phosphorylation, suggesting that activated MerTK maintains a rounded cell morphology, 
most probably by ROCK-RhoA-mediated myosin IIA activity. This hypothesis merits further 
investigation. We will continue this study and elucidate the complete map of the MerTK 
signaling network. Importantly, this work should contribute to the development of anti-
invasive/pro-apoptotic therapeutic interventions.  
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MAP Kinase-Interacting Kinase 1 Regulates SMAD2-
Dependent TGF-bSignaling Pathway in HumanGlioblastoma
Michal Grzmil1, Pier Jr Morin1, Maria Maddalena Lino2, Adrian Merlo2, Stephan Frank3, Yuhua Wang1,
Gerald Moncayo1, and Brian A. Hemmings1
Abstract
Glioblastoma multiforme (GBM) is the most common aggressive brain cancer with a median survival of
approximately 1 year. In a search for novel molecular targets that could be therapeutically developed, our
kinome-focused microarray analysis identified the MAP (mitogen-activated protein) kinase-interacting kinase 1
(MNK1) as an attractive theranostic candidate. MNK1 overexpression was confirmed in both primary GBMs and
glioma cell lines. Inhibition of MNK1 activity in GBM cells by the small molecule CGP57380 suppressed eIF4E
phosphorylation, proliferation, and colony formation whereas concomitant treatment with CGP57380 and the
mTOR inhibitor rapamycin accentuated growth inhibition and cell-cycle arrest. siRNA-mediated knockdown of
MNK1 expression reduced proliferation of cells incubated with rapamycin. Conversely, overexpression of full-
length MNK1 reduced rapamycin-induced growth inhibition. Analysis of polysomal profiles revealed inhibition
of translation in CGP57380 and rapamycin-treated cells. Microarray analysis of total and polysomal RNA from
MNK1-depleted GBM cells identified mRNAs involved in regulation of TGF-b pathway. Translation of SMAD2
mRNA as well as TGF-b–induced cell motility and vimentin expression was regulated by MNK1 signaling. Tissue
microarray analysis revealed a positive correlation between the immunohistochemical staining of MNK1 and
SMAD2. Taken together, our findings offer insights into how MNK1 pathways control translation of cancer-
related mRNAs including SMAD2, a key component of the TGF-b signaling pathway. Furthermore, they suggest
MNK1-controlled translational pathways in targeted strategies to more effectively treat GBM. Cancer Res; 71(6);
2392–402. 2011 AACR.
Introduction
In the last decade, genetic profiling of brain tumors has
improved our understanding of gliomagenesis and led to the
development of many targeted therapies based on molecular
interference with deregulated signaling networks (1–3).
Although many screens have characterized and proposed
the targeting of deregulated signaling pathways for thera-
peutic interference, recent reports have identified therapy
resistance based on the compensatory activation of
alternative signaling pathways. Thus, effective treatment
requires combined regimens targeting the glioblastoma
kinome (4–7).
The overall rate of protein synthesis is an important deter-
minant of cancer cell metabolism (8). Many previous observa-
tions have indicated that deregulated growth pathways in
human cancers are involved in the control of translation
supporting cell proliferation and survival. In response to
nutrients and growth factors, activated AKT/mTOR pathways
enhance global protein synthesis. They phosphorylate and
inactivate the eukaryotic translation initiation factor 4E-bind-
ing protein (eIF4E-BP), a repressor of mRNA translation and
activate ribosomal S6 kinase 1 (S6K1) involved in ribosome
biogenesis (9). Kinases associated with translation initiation
complexes have a potential for regulating translation. MAP
(mitogen-activated protein) kinase-interacting kinases
(MNK1/2) can bind to translation initiation factor, eIF4G,
and phosphorylate the cap-binding protein, the translation
initiation factor eIF4E (10). The phosphorylation of eIF4E on
Ser209 is increased in cancer cells and eIF4E expression levels
are upregulated in many tumors (11–13). Recent findings
demonstrate that eIF4E phosphorylation by MNKs is abso-
lutely required for the eIF4E activity that opposes apoptosis
and promotes tumorigenesis in vivo (14). In addition, MNKs
can also phosphorylate RNA-binding protein, hnRNPA1,
which binds AU-rich elements of messenger RNA (e.g.,
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TNF-a), thereby regulating its stability and/or translation (15).
Thus, MNK signaling appears to play an important role
in posttranscriptional regulation of cancer-related gene
expression.
Materials and Methods
Antibodies and chemicals
MNK1 (C4C1), p-MNK1 (Thr197/202), SMAD2 (86F7), p-
SMAD2 (Ser245/250/255), eIF4E (C46H6), p-eIF4E (Ser209), p-
S6 (Ser235/236), p38 (9212), p-p38 (Thr180/Tyr182), ERK1/2
(9102), p-ERK1/2 (Thr202/Tyr204), and p-EGFR (Tyr992) anti-
bodies were from Cell Signaling. Actin (I-19) and EGFR
(epidermal growth factor receptor; sc-03) antibodies from
Santa Cruz Biotechnology, vimentin (V9) from Thermo Scien-
tific and generated a-tubulin YL1/2 was used as hybridoma
supernatant. CGP57380 and rapamycin were from Sigma,
RAD001 from Novartis, SB431542 from Tocris, and TGF-b
from PeproTech.
Patients
Primary glioma tissues obtained from the operating room
were processed as previously described (16) in accordance
with the guidelines of the Ethical Committee of the University
Hospitals of Basel and Dusseldorf. Tumors were diagnosed
and graded according to the current WHO Classification. The
patient set is summarized in Supplementary Table 1.
Cell culture and standard techniques
Human glioma cells: BS125, LN18, LN229, BS149, LN319,
LN405, LN215, LN71, U343MG, U373, U87MG, Hs683, A172, and
M059K were cultured in DMEM supplemented with 10% FCS
(fetal calf serum) and antibiotics at 37C and 5% CO2. Glio-
blastoma multiforme (GBM)–derived BS287 spheres were cul-
tured as described previously (17). Clonetics normal human
astrocytes (NHA) were from Cambrex and cultured according
to the manufacturer's recommendations. Transfection, treat-
ments, cellular assays, including proliferation, viability, colony
formation, flow cytometry as well as RNA and protein isolation
followed by quantitative real-time PCR, microarray hybrid-
ization, Western blotting, and immunohistochemistry are
described in Supplementary Experimental Procedures.
Microarray data analysis
Data mining and visualization of microarray-profiled glio-
mas were performed using Genedata's Analyst 4.1 package.
Median fold ratio values at P < 0.05 in the t test were used for
analysis. All samples were quintile normalized and median
scaled to correct for minor variations in their expression
distributions. The data obtained have been deposited in the
Gene Expression Omnibus (GEO) database (GSE15824). Poly-
somal profiles (triplicate experiment for transfection and
inhibitor treatments) and RNA extraction was accomplished
as previously described (18) and used for microarray hybri-
dization described in Supplementary Material. Data analysis
was carried out using R/Bioconductor (19). Signal condensa-
tion was performed using the RMA from the Bioconductor
Affy package. Differentially expressed genes were identified by
the empirical Bayes method (F test) implemented in the
LIMMA package and adjusted with the false discovery rate
method (20). Visualization was done in R. Probe sets with a
log2 average contrast signal of at least 5, an adjusted P value of
< 0.05, and an absolute log2 fold-change of greater than 0.585
(1.5-fold in linear space) were used.
Cell motility
Forty-eight hours after transfection or 24 hours after treat-
ment, a scratch was made and the migration of cells was
monitored using a live-imaging system Widefield TILL5, Long
Run, Axiovert 200M (Carl Zeiss). Images were captured every
20 minutes over a period of 22 hours with a CCD camera using
MetaMorph software (Molecular Devices) and analyzed using
ImageJ software (NIH).
Results
MNK1 overexpression in human glioblastoma
Microarray analysis of 30 brain tumor samples was per-
formed including 15 high-grade gliomas (glioblastomas) and
15 low-grade tumors (8 astrocytomas and 7 oligodendroglio-
mas). Kinase expression in each tumor was normalized to the
expression levels in normal brain and expression values from
NHAs were used as an additional control. Apart from kinases
known to be associated with gliomagenesis (e.g., EGFR; data
not shown), a further protein kinase was found to be upre-
gulated in primary glioblastomas. The transcript level of
MNK1 was upregulated more than 2-fold in 12 of 15 glioblas-
tomas and in 5 of 8 astrocytomas (P < 0.01 for both groups,
compared with expression in normal brain and human normal
astrocytes) whereas 3 of 7 patients exhibited elevated MNK1
levels in oligodendroglioma (Fig. 1A). MNK2 kinase expression
was not significantly altered in the human gliomas analyzed
(data not shown). There was no significant correlation
between MNK1 expression and survival in profiled glioma
patients. Changes in MNK1 expression were further validated
by real-time PCR. In 10 of 11 glioblastoma samples, MNK1 was
elevated more than 2-fold (Fig. 1B). Human MNK1 arises from
an alternatively spliced transcript giving rise to 2 isoforms,
longer MNK1a (50 kDa) and a shorter MNK1b variant (38 kDa)
that lacks 89 C-terminal amino acids (21). We determined
MNK1a protein levels in GBM tumors and cell lines using an
MNK1a-specific monoclonal antibody. An increase in MNK1
kinase was observed in 14 of 20 (70%) primary glioblastomas
and in 11 of 13 (84%) glioma cell lines, compared with normal
brain and NHAs, respectively (Fig. 1C). Immunohistochemical
analysis of tumor sections from 12 GBM patients and tissue
arrays containing 34 GBMs and 5 normal brains also demon-
strated high MNK1 protein levels, with stronger cytoplasmic
signals in GBM cells than in weakly stained normal brain
(Fig. 1D). Antibody specificity was tested on whole protein cell
lysates (Fig. 1C) and on formalin-fixed BS125 cells (Fig. 1D)
transfected with siRNA against the MNK1 gene or luciferase
(control). MNK1 phosphorylation correlated with total level of
MNK1 (correlation coefficient ¼ 0.51) and was significantly
higher in 7 of 11 (64%) GBM patients than in normal human
brain and astrocytes (Fig. 1C and Supplementary Fig. S1). To
MNK1 Regulates TGF-b/SMAD2 Pathway
www.aacrjournals.org Cancer Res; 71(6) March 15, 2011 2393
 American Association for Cancer Research Copyright © 2011 
 on October 17, 2011cancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst March 14, 2011; DOI:10.1158/0008-5472.CAN-10-3112
investigate whether MNK1 expression is regulated by EGFR,
which is often amplified and hyperactivated in GBM, the
correlation between MNK1 and EGFR was analyzed in glioma
patients and in GBM cell lines. Microarray analysis showed no
significant correlation between MNK1 and EGFR in human
gliomas (correlation coefficient ¼ 0.29). There was also no
correlation between MNK1 and EGFR or phopho-EGFR levels
in analyzed GBM cells (Fig. 1C and Supplementary Fig. S2).
Likewise, treatment with the EGFR inhibitor AEE788 did not
affect the MNK1 protein level indicating that MNK1 expres-
sion is not regulated by EGFR pathways.
Inhibition of MNK1 reduces GBM cell proliferation and
colony formation and acts additively with rapamycin
To investigate MNK1 as a potential therapeutic target, a
pharmacologic approach was first taken using an efficient
inhibitor of MNK kinases, CGP57380 (22). As MNK1 signaling
is involved in the regulation of translation, inhibition of MNK1
was combined with the targeting of mTOR pathways, which
also act at the translational level. Treatment with either
CGP57380 or rapamycin alone reduced proliferation and their
combination had an additive effect on human GBM cell lines
BS125, LN319, LN405, and BS287 spheres (Fig. 2A and Sup-
plementary Fig. S3). There was a synergistic effect at the
highest concentrations of CGP57380 (10 mmol/L) and rapa-
mycin (10 nmol/L), with combination index values of 0.71 and
0.63 in BS125 and LN319 cells, respectively. Concomitant
treatments with CGP57380 and rapamycin over 5 days greatly
reduced BS125 and LN319 cell number (data not shown). The
observed additive inhibitory effect was confirmed further
using CGP57380 together with the rapamycin derivative
RAD001 in BS125 cells (Supplementary Fig. S3). The effects
of inhibitor treatments were monitored by immunoblotting
using phospho-specific antibodies against eIF4E (treatment
with CGP57380) and ribosomal protein S6 (treatment with
rapamycin; Fig. 2B, right). CGP57380 at 2 mmol/L or rapamycin
at 0.5 nmol/L was sufficient to decrease significantly eIF4E
and S6 phosphorylation, respectively. Furthermore, the
growth of BS125 cells in soft agar at increasing concentrations
of CGP57380 and rapamycin was inhibited in a dose-depen-
dent manner (Fig. 2B, left). Concomitant treatment with
CGP57380 and rapamycin amplified inhibitory effect;
CGP57380 at 2 mmol/L significantly increased the growth
inhibition by rapamycin. To analyze the relationship specifi-
cally between MNK1 protein level and cell proliferation after
rapamycin treatment, RNAi (RNA interference) was used to
Figure 1. Expression of MNK1 in
human gliomas. A, MNK1
transcript levels in primary brain
tumors obtained from microarray
analysis. NHA, Oligo
(oligodendroglioma), Astro
(astrocytoma), and GBM.
Expression of MNK1 in normal
brain (NB) was set to 1. Patient
information is given in
Supplementary Table 1. B,
quantitative RT-PCR analysis of
MNK1 (normalized to EEF1A1
expression) on total RNA isolated
from glioblastoma and 2 NB: I and
II samples. C, Western blot
analysis using an MNK1-specific
antibody on whole protein lysates
obtained from human GBM (lanes
1–22), NB samples as well as from
different GBM cell lines, NHA and
BS125 cells at 3 days after
transfection with increasing
concentrations of duplex siRNA
againstMNK1or against luciferase
(control). Blots were stripped and
reprobed with an a-tubulin
antibody. Ratios (R) of MNK1-
specific signals relative to tubulin
expression are shown below. The
MNK1/tubulin ratio for NB was set
to 1. D, immunohistochemistry
(IHC) of MNK1 in normal brain and
primary GBM in tissue arrays (i),
GBM paraffin sections (ii), and
formalin-fixed BS125 cells 72
hours after siRNA transfection (iii);
bar, 20 mm.
Grzmil et al.
Cancer Res; 71(6) March 15, 2011 Cancer Research2394
 American Association for Cancer Research Copyright © 2011 
 on October 17, 2011cancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst March 14, 2011; DOI:10.1158/0008-5472.CAN-10-3112
Figure 2. Targeting MNK1 inhibited
cell growth and sensitizedGBMcells
to rapamycin. A, an MTT-based
assay of BS125 and LN319 cell
proliferation after 3 days of
incubation with CGP57380 alone or
in combinationwith rapamycin (Rap).
Results were obtained in triplicate
and are shown as % proliferation
comparedwith control cells. Bottom,
corresponding combination index
(CI) values greater than 1.1 indicate
antagonism, between 0.9 and 1.1
additive effects, and lower than 0.9
synergism. B, resuspended BS125
cells in soft agar were incubated
at the indicated concentrations of
CGP57380 and/or rapamycin. After
16 days, colonies were
photographed and analyzed as
described in the Materials and
Methods section. All experiments
were carried out in triplicate and the
results are shown as mean values 
SD. Right, phosphorylation of eIF4E
(Ser209) or ribosomal protein S6
(Ser235/236) in BS125 cells treated
with CGP57380 or rapamycin for
24 hours was monitored by
immunoblotting using phospho-
specific antibodies. The blots were
stripped and reprobed with
antitubulin antibody to control for
equal loading. C, BS125 cells were
transfected with duplex siRNA
oligonucleotides against MNK1 (si)
or with a control duplex against
luciferase. For the full-length MNK1
overexpression, cells were
transfected with a MNK1–Flag
construct or an empty control vector.
Twenty-four hours after transfection,
cells were treated with rapamycin at
the concentrations indicated for a
further 48 hours and used for MTT-
based assay as described above.
Bottom, whole protein lysates
isolated from transfected and
rapamycin-treated cells were
subjected to Western blot analysis
using phospho-specific (Thr197/
202) and total MNK1 antibodies.
Actin- or tubulin-specific antibodies
were used as loading controls.
D, eIF4E phosphorylation in MNK1-
depleted or overexpressing BS125
cells 48 hours after transfection or
treatmentwith 10 mmol/L CGP57380
was analyzed by Western blot using
specific antibodies against
phosphorylated and total eIF4E.
Right, changes in eIF4E
phosphorylation depicted as the
ratio of phospho- to total eIF4E-
specific signals. Ratios in controls
were normalized to 1. *, P < 0.05 or
**, P < 0.02 compared with control
or single drug treatment using
Student's t test.
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inhibit MNK1 expression. For complete depletion of MNK1,
duplex siRNA were used specific for splice variants MNK1a
and MNK1b, which encode identical catalytic domains. BS125
cells transfected with an MNK1-specific siRNA duplex showed
significantly reduced endogenous expression of both phos-
pho- and total MNK1 protein and enhanced sensitivity to
rapamycin (Fig. 2C). To investigate this further, a full-length
MNK1–Flag fusion protein was overexpressed in BS125 cells.
Ectopically expressed MNK1 protein was phosphorylated and
this reduced the inhibition of BS125 cell proliferation by
rapamycin (Fig. 2C, right). MNK1 overexpression increased
phosphorylation of the MNK1 substrate eIF4E more than 2-
fold, indicating that the MNK1-Flag–tagged kinase was fully
functional whereas MNK1-specific knockdown or CGP57380
treatment reduced eIF4E phosphorylation to 51% and 7%,
respectively, compared with control-treated cells (Fig. 2D).
Finally, the MNK1 protein level correlated positively (correla-
tion coefficient ¼ 0.7) with resistance to mTOR inhibition
after 3 days treatment with 5 nmol/L rapamycin in 6 GBM cell
lines: BS125, LN319, LN18, LN405, U343MG, and BS145
(Fig. 2A, Supplementary Fig. S3, and data not shown).
Targeting signaling pathways regulating translation
reduces global translation and induces cell-cycle arrest
Polysome profiles obtained by sucrose gradient centrifuga-
tion revealed a substantial increase in the inhibition of global
translation in BS125 cells treated simultaneously with
CGP57380 and rapamycin (Fig. 3A). Comparison analysis of
the areas occupied under the curves in polysomal profiles
(data not shown) indicates that CGP57380 increased the
relative abundance of free ribosomes (1.35  0.3-fold) and
decreased polysomes (0.65  0.05) whereas rapamycin alone
Figure 3. Inhibition of MNK1 by
CGP57380 reduced global
translation and induced cell-cycle
arrest; combined treatment with
rapamycin increased the inhibitory
effect. A, polysome profiles from
BS125 cells treated with DMSO
(dimethyl sulfoxide; control), 10
mmol/L CGP57380, and/or 10
nmol/L rapamycin for 24 hours.
The A254 peaks corresponding to
ribosomal subunits and
polysomes are indicated. B, cell
division was determined 72 hours
after treatment (as described
above) using the CFSE
(carboxyfluorescein succinimidyl
ester) cell-labeling assay followed
by FACS (fluorescence-activated
cell-sorting) analysis. The
rapamycin derivative RAD001 was
used at 10 nmol/L. *, P < 0.05 or **,
P < 0.01 versus control or single
treatment. C, cell-cycle analysis of
BS125 cells treated for 24 hours
as indicated above. Results are
means  SD from 3 independent
incubations.
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significantly reduced the abundance of polysomes (0.43 
0.04) compared with control. Cotreatment with CGP57380 and
rapamycin both increased free ribosomes (1.48  0.23) and
reduced polysomes abundance (0.31  0.05). Furthermore, as
shown in Figure 3B and C, the inhibition of global translation
was accompanied by G1 cell-cycle arrest. This demonstrates a
major cytostatic effect in BS125 cells treated with CGP57380
together with rapamycin or RAD001.
Identification of MNK1-regulated targets
Sucrose gradient separation revealed no major differences
in polysome profiles between BS125 cells transfected with
siRNA against MNK1 and the control duplex (Fig. 4A and B),
suggesting that MNK1 is involved rather in the regulation of a
small subset of mRNAs. To investigate this further, total and
polysome-associated RNAs isolated from the same transfected
cells were compared using microarray hybridization. In addi-
tion to reduced MNK1 expression, we identified 56 differen-
tially expressed mRNAs (P < 0.05) using polysomal RNA and 29
using total RNA (Fig. 4C, Supplementary Tables S2 and S3). Of
these, 5 targets were common to both polysomal and total
RNAs. The identified MNK1 targets have been subjected to
gene ontology and pathway analysis using the DAVID web-
based bioinformatics tool (23, 24). These analyses indicated
that MNK1 regulates a group of mRNAs encoding proteins
involved in TGF-b signaling, with the highest enrichment
value of 8.3 whereas mRNAs associated with signal transduc-
tion and cell communication showed 3.1- and 2.6-fold enrich-
ment, respectively (Table 1). Of note, the SMAD2 transcript
was present in all 3 identified gene groups, suggesting that
SMAD2 expression plays an important role in the MNK1-
regulated phenotype.
MNK1 regulates SMAD2-dependent TGF-b pathways in
human GBM
The microarray data demonstrating decreased SMAD2
mRNA association with polysomes (Fig. 5A) were further
validated by RT-PCR analysis of polysomal and total RNA
(Fig. 5B) or at the protein level in MNK1-depleted BS125 and
LN319 cells (Fig. 5C). SMAD2 protein was also reduced at the
presence of RNA polymerase II inhibitor, actinomycin D,
indicating posttranscriptional regulation. In addition, the
SMAD2 protein level was found to be higher in MNK1-over-
expressing BS125 stable clones than in control-transfected
cells (Fig. 5C, bottom). To further validate the in vitro data,
tissue arrays were used to analyze MNK1 and SMAD2 expres-
sion at the protein level in 34 GBM tumors and 5 normal
brains, as described above. Strong MNK1 and SMAD2 immu-
nostaining was recorded in comparable areas of analyzed
tumors, whereas normal brain tissue showed significantly
weaker expression (Fig. 5D). Comparative bioinformatics
analysis of MNK1 and SMAD2 expression gave a correlation
coefficient of 0.6, supporting our in vitro observation that
MNK1 regulates SMAD2 protein levels in human GBM.
Exploring how far MNK1 may be involved in the regulation
of TGF-b/SMAD–dependent phenotype, we found that TGF-b
at 5 nmol/L is sufficient to increase cell motility of BS125 and
Hs683 cells compared with untreated cells (data not shown).
Furthermore, siRNA knockdown of MNK1 or inhibition by
CGP57380 reduced total as well as TGF-b–induced phos-
phorylated SMAD2 levels and led to a pronounced inhibition
of cellular motility (Fig. 6A). Bioinformatics analysis of micro-
array data from GBM patients revealed a significant correla-
tion between MNK1 expression and TGF-b–regulated genes.
For this analysis, we chose hallmarks of the epithelial to
Figure 4.MNK1 knockdown had no major impact on global translation but regulated the expression of a subset of mRNAs. A, polysome profiles from BS125
cell lysates prepared 48 hours after transfection with duplex siRNA against MNK1 gene (si) or with a control duplex against luciferase. The A254 peaks
corresponding to ribosomal subunits and polysomes are indicated. B, the same protein lysates were subjected to Western blot analysis with MNK1- and
tubulin-specific antibodies. *, profiles in A were obtained from the indicated lysates. C, results from expression profiling of total and polysome-associated
mRNAs from MNK1-depleted and control-transfected BS125 cells shown as a Venn diagram representing the numbers of significantly affected RNAs.
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mesenchymal transition (EMT) that plays a crucial role in
malignant cancer cell migration and motility (25). Expression
of vimentin and fibronectin positively correlated with MNK1
expression levels (correlation coefficients ¼ 0.74 and 0.70,
respectively), whereas, E-cadherin and tight junction protein 1
showed negative correlations of0.64 and 0.65, respectively
(Fig. 6B). Decreased vimentin expression was further con-
firmed at the protein level in MNK1-depleted BS125 GBM cells
(Fig. 6B) whereas E-cadherin expression was not detected by
Western blotting (data not shown). The lack of vimentin and
other TGF-b–regulated EMT markers among the MNK1-regu-
lated mRNAs (Supplementary Tables S2 and S3) may be
explained by the fact that microarray analyses were performed
48 hours after transfection, which was sufficient for MNK1
knockdown at the protein level, whereas a significant decrease
in SMAD2 protein was only observed after 72 hours (Fig. 5C).
As only a marginal decrease in SMAD2 protein expression was
reached 48 hours after transfection, we concluded that a
significant decrease in SMAD2 protein synthesis begins after
that time point resulting in alterations in TGF-b/SMAD2
signaling pathways.
In this study, we showed that SMAD2 protein synthesis
depends on MNK1 and that targeting MNK1 sensitizes GBM
cells to rapamycin. Therefore, we asked whether inhibition of
the TGF-b/SMAD2 pathway, instead of MNK1, also has an
additive effect. For this, we made use of the SB431542 com-
pound known to inhibit SMAD2 phosphorylation (26). As
demonstrated in Supplementary Figure S4, concomitant treat-
ment with SB431542 and rapamycin (or RAD001) for 5 days
had an inhibitory effect on GBM cell growth (27%–30% of
control) similar to that in cells treated with CGP57380, rapa-
mycin or RAD001 (20%–23%). Targeting all 3 pathways
(mTOR, SMAD2, and MNK1) did not increase the inhibitory
effect (20%–22%) and concomitant treatment with CGP57380
and SB431542 was not additive. Finally, as shown in
Figure 6C, TGF-b treatment induced activation of MNK1
upstream kinases p38 and ERK1/2, and increased MNK1
phosphorylation, thus supporting our model for MNK1 and
TGF-b/SMAD2 pathways convergence (Fig. 6D).
Discussion
The biological function of eIF4E phosphorylation at Ser209
by MNKs has long been controversial. Some studies have
reported that eIF4E phosphorylation enhances translation
in general (27), whereas others concluded that it has no effect
or even reduces translation (22, 28). Our analysis of polysome
profiles from MNK-depleted cells revealed that growth inhibi-
tion occurs as a result of reduced translation, arguing for
positive regulation of translation via the MNK/eIF4E pathway.
Although eIF4E is known to be a general translation factor, it
can also preferentially enhance the translation of carcinogen-
esis-associated mRNAs, including regulators of the cell cycle,
apoptosis, angiogenesis and invasion (29–32). Therefore, it is
very likely that CGP57380-mediated reduction of translation
and G1 cell-cycle arrest results from inhibition of the selective
translation of MNK-regulated, growth-promoting transcripts.
Furthermore, analysis of polysomal profiles prepared from
MNK1-depleted glioblastoma cells indicated that MNK1 sig-
naling is not required for global translation. As previously
reported, mice lacking both Mnk1 andMnk2 develop normally
and eIF4E phosphorylation at Ser209 does not occur, even
when MNK upstream kinases are activated (33). These results
demonstrate that MNK signaling is not crucial for normal
growth; although, MNK activity may be necessary for growth
and survival under certain conditions, for example particular
stresses or cancer states. Indeed, in the same model, loss of
MNK function sensitized mouse fibroblasts to apoptosis
induced by serum withdrawal suggesting a function in adap-
tive responses to stress (34). Similarly, arsenic-induced apop-
tosis was enhanced in cells with targeted disruption of MNK
genes (35). Thus, our results together with the previously
published data, promote elevated MNK activity in human
glioblastoma as an attractive therapeutic target for 2 reasons.
First, MNK signaling is not required for normal cell growth or
development. Second, its inhibition may neutralize the cellular
stress responses that aid cancer cell survival and are triggered
by many therapies.
The different degree of translation reduction in CGP57380-
treated cells compared with MNK1-specific knockdown (Figs.
3 and 4) may be explained by the fact that CGP57380 targets
all human MNKs and inhibits eIF4E phosphorylation almost
completely whereas MNK1 knockdown reduces the phos-
phorylated form of eIF4E by 50%, presumably due to an
MNK2 compensatory function. In our study, similar effects
were also observed in proliferation assays, where CGP57380
had a more dramatic effect on cell phenotype than a genetic
approach using MNK1-specific knockdown. We found MNK1,
but not MNK2, to be overexpressed in human gliomas.
Although the 2 kinases share eIF4E as a substrate, they exhibit
70% identity in their catalytic domains (36), potentially indi-
cating regulation of different downstream pathways. An
MNK1-specific role that is not compensated by MNK2 has
already been proposed from the results of experiments in
which reintroduction of wild-type Mnk1, but not Mnk2,
Table 1.Bioinformatics analysis ofMNK1-regu-
leted genes identified by microarray hybridiza-
tion. Enrichment was scored for terms with
P < 0.05 for a group of at least 3 genes.
Functional annotations for
MNK1-regulated genes
Enrichment
TGF-b signaling pathway (pathway:
hsa04350, P ¼ 0.04); SMAD2,
BMP8, DP1
8.3
Regulation of signal transduction
(GO:0009966, P ¼ 0.01);
regulation of cell communication
(GO:0010646, P ¼ 0.02); CTGLF3,
CTGLF5, GPR89B, SMAD2, TGIF,
RAC1, SNX13, TLR4,
TNFSF15
3.1; 2.6
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rescued the starvation-induced apoptotic phenotype of mouse
embryonic fibroblasts from mnk1/2 double-knockout animals
(34). Furthermore, in the most recent study, MNK1-specific
knockdown in U87MG cells was sufficient to reduce tumor
formation in mouse xenograft model (37) suggesting that
MNK1 plays an essential role in gliomagenesis. Therefore,
to investigate the role of MNK1 in regulation of gene expres-
sion, we used a genetic approach for specifically knocking
down MNK1 expression. Our microarray analysis detected 80
MNK1-dependent mRNAs, with 56 of them using polysomal
RNA, indicating that MNK1-dependent gene expression is
regulated mainly at the translational level. In a previous study,
translation of the antiapoptotic protein Mcl-1 was found to be
regulated by eIF4E phosphorylation, thus supporting a role for
MNK1 signaling in lymphoma cell survival (14). A more recent
study using CGP57380 compound and an array of 263 prostate
carcinoma-related genes identified new translationally regu-
lated MNK targets involved in the response to hypoxia-indu-
cible factor (HIF1a) and cell-cycle regulation (cyclin-
dependent kinases and inhibitors) in prostate cancer cells
(38). Our screen used a genetic approach together with a
genome-wide microarray to identify MNK1-specific–regulated
genes. The fact that this screen did not identify previously
described MNK targets may be due to GBM cell specificity. In
addition, by targeting MNK1 (but not MNK2 or eIF4E phos-
phorylation), we identified anMNK1-specific subset of mRNAs
Figure 5. MNK1 regulated SMAD2 translation in human glioblastoma. A, SMAD2 transcript levels obtained by microarray analysis of total and polysomal
RNA from MNK1-depleted and control-transfected BS125 cells. Expression of SMAD2 in controls was set to 1. *, P < 0.05 or nonsignificant (ns) versus
controls. B, microarray data validation by semi–quantitative RT-PCR analysis using SMAD2 and GAPDH (control) specific primers. C, BS125 and
LN319 whole cell protein lysates prepared 48 or 72 hours after transfection with duplex siRNA against MNK1 or with a control duplex against luciferase were
subjected to Western blot analysis using antibodies specific to total SMAD2, MNK1, and tubulin, as an equal loading control. In addition, 48 hours after
transfection, BS125 cells were further incubated with 1 mmol/L of actinomycin D for the next 24 hours and the protein lysates were analyzed as
described above. Bottom, SMAD2 and MNK1 expression analyzed by Western blotting in stable BS125 cell clones overexpressing the full-length
HA-MNK1 fusion protein and control cells transfected with an empty vector. D, examples of immunostaining for MNK1 and SMAD2 in GBM tumors.
Slides were stained with MNK1- or SMAD2-specific monoclonal antibodies (brown) and counterstained with hematoxylin (blue); bars, 50 and 20 mm.
Right, expression of MNK1 and SMAD2 obtained by tissue array analysis in 34 GBM patients and 5 normal brains (NB).
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that may be different to MNK2- or phospho-EIF4E–regulated
target gene groups.
Genetic or pharmacologic targeting of MNK1 reduced
total and phosphorylated SMAD2 levels as well as TGF-
b–associated cell motility of glioma cells indicating that
MNK1 regulates not only one of the main transducers of
TGF-b signals but also an TGF-b/SMAD2–dependent phe-
notype. The correlation between EMT markers and MNK1
expression in GBM patients, and the reduced vimentin
expression in MNK1-depleted GBM cells, suggest MNK1
regulation of TGF-b–induced gene expression. In addition,
the correlation found between MNK1 and SMAD2 protein
expression in human GBMs further supports our model in
GBM patients. SMAD2 is one of the major signal transducers
during TGF-b pathway activation. Previous studies showed
that high TGF-b/SMAD activity in human glioma patients
correlated with poor prognosis and was dependent on
platelet-derived growth factor beta (PDGFB) expression
(39) and a more recent report demonstrates that TGF-b
can induce the self-renewal capacity of glioma-initiating
cells in a SMAD-dependent manner (40). In our study,
MNK1 expression correlated with PDGFB in primary GBM
patients (correlation coefficient ¼ 0.56, data not shown)
and targeting MNKs reduced GBM-derived spheres growth
Figure 6. MNK1 signaling regulated TGF-b–induced glioma cell motility. A, BS125 and Hs683 cells were transfected with duplex siRNA oligonucleotides
against the MNK1 gene (si) or luciferase (control). A scratch was made 48 hours after transfection or 24 hours after treatment with 10 mmol/L CGP57380 or
DMSO (control) and cellular motility was monitored in the presence of 5 nmol/L TGF-b. After 22 hours, the scratch "wound" recovery was
set to 100% in control cells. All experiments were assayed in triplicate and results shown as means  SD. Bottom, whole protein lysates isolated from
transfected and/or treated cells (as described above) were subjected to Western blot analysis using p-SMAD2 (Ser245/250/255), SMAD2, MNK1, and
tubulin antibodies. B, correlation coefficients of the comparison of MNK1 and EMT markers in 15 GBMs and 2 normal brain samples. VIM, vimentin;
FN1, fibronectin; CDH1, E-cadherin; and TJP1, tight junction protein 1. Right, MNK1-dependent expression of vimentin analyzed by Western blotting in
MNK1-depleted BS125 cells after duplex siRNA transfection and TGF-b treatment as described above. C, expression of p-p38 (Thr180/Tyr182), p38,
p-ERK1/2 (Thr202/Tyr204), ERK1/2, p-MNK1 (Thr197/202), and MNK1 was analyzed by Western blotting in BS125 cells treated with 5 nmol/L TGF-b at
indicated time points or for 24 hours. D, model for MNK1 and TGF-b pathway convergence. Overexpressed and activated MNK1 kinase increases SMAD2
translation thereby contributing to signaling of canonical (i) TGF-b pathways via SMAD2/3/4 complexes that interact with transcription factors (TF) and
induce expression of genes involved in proliferation, motility, and survival of malignant GBM cells. Hyperactivated TGF-b receptors (TbRI and TbRII) can also
activate noncanonical pathways (ii) leading to phosphorylation of ERKs and p38 kinases and activation of MNK1 that can further increase translation of
specific mRNAs involved in cancer progression.
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suggesting that MNK1 signaling supports TGF-b activity in
malignant gliomas.
In invasive cancers, TGF-b signaling has a tumor-promoting
effect supporting cell motility, invasion, angiogenesis, immu-
nosuppression, and EMT (41). Interestingly, noncanonical
TGF-b signaling pathways can activate ERKs and p38 kinases
(42) that phosphorylate and activate MNKs. In agreement with
previous study, TGF-b induced ERK and p38 activity as well as
MNK1 phosphorylation in GBM cells. Therefore, our data
together with previous observations propose a model whereby
activation of MNK1 and TGF-b pathways and their mutual
regulation support GBM progression (Fig. 6D).
A balance between MNK activity and mTOR pathways was
reported in prostate and lung cancer cells, where downregula-
tion of one pathway was correlated with the activation of
another, resulting in a defined level of translation that sup-
ported cancer cell survival (38, 43). In agreement with a recent
study, simultaneous blocking of the MNK and mTOR path-
ways significantly blocked GBM cell proliferation, colony
formation, and tumor sphere growth. We observed a marked
additive effect on translation inhibition and G1 cell-cycle
arrest compared with the single treatment, thus also indicat-
ing a therapeutic potential of targeting MNK and mTOR
pathways against certain tumor entities including malignant
gliomas.
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6.2   Generation of MerTK monoclonal antibody  
(In collaboration with Susanne Schenk, FMI) 
Kinase domain 
Ig-like domains 
fibronectin type III repeats 
MerTK 
The recombinant GST-tagged human MerTK (amino acids 536-999; from Janis Liebetanz, 
Doriano Fabbro, Novartis) was used as antigen to generate MerTK monoclonal antibody. 
Supernatants from hybridoma cells were screened by ELISA with MBP-tagged human 
MerTK (amino acids 536-999) as the antigen, and by western blotting on U373, K562 and 
U937 whole cell extracts. Primary hybridoma clones were subcloned by limiting dilution.  
Figure 1: Schema of Mer receptor tyrosine kinase 
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Figure 3. Validation of subclones recognizing three TAM receptors. 1. Protein lysates of 293 cells 
expressing pcDNA3-Axl-HA; 2. Purified GST-Tyro3-ICD. 3. Protein lysates of U373 cells stably 
expressing full-length MerTK. 
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Table 1. Summary of  MerTK monoclonal antibody clones 
clone 
ELISA 
orig
. Western subcloning final clone isotype comments 
57A 0.917  pos.       keep 
15B 0.871  pos.  --     keep 
88B 0.903  pos.  --     keep 
38D 0.905  pos. subclone       
59E 0.958 pos. subclone       
87F 1.061 pos.  --     keep 
5H 0.947 pos.  --     keep 
58H 0.894 pos. subclone       
12I 1.052 pos. subclone       
30M 0.811 pos. subclone       
15R 0.968 pos. subclone       
64R 0.881 pos. subclone       
78R 0.905 pos. subclone       
28S 0.896 pos.  --     keep 
30S 0.837 pos.       keep 
49S 0.926 pos. subclone       
57S 0.852 pos. subclone       
71S 0.863 pos.  --     keep 
Yellow: Clones recognizing endogenous MerTK 
Blue: Clones recognizing all three overexpressed TAM receptors 
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